Nothing Special   »   [go: up one dir, main page]

WO1997031910A1 - Fibrinogen receptor antagonists - Google Patents

Fibrinogen receptor antagonists Download PDF

Info

Publication number
WO1997031910A1
WO1997031910A1 PCT/US1997/002712 US9702712W WO9731910A1 WO 1997031910 A1 WO1997031910 A1 WO 1997031910A1 US 9702712 W US9702712 W US 9702712W WO 9731910 A1 WO9731910 A1 WO 9731910A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
substituted
mono
aryl
unsusbstituted
Prior art date
Application number
PCT/US1997/002712
Other languages
French (fr)
Inventor
John Wai
Mark E. Duggan
Thorsten E. Fisher
George D. Hartman
James J. Perkins
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606489.4A external-priority patent/GB9606489D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to AU21332/97A priority Critical patent/AU712082B2/en
Priority to EP97906712A priority patent/EP0885205A4/en
Priority to JP9531013A priority patent/JP2000505471A/en
Publication of WO1997031910A1 publication Critical patent/WO1997031910A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the invention relates generally to modulating cell adhesion and to inhibiting the binding of fibrinogen and other proteins to blood platelets, and inhibiting the aggregation of blood platelets specifically to the gp Ilb/IIIa fibrinogen receptor site.
  • Fibrinogen is a glycoprotein present in blood plasma that participates in platelet aggregation and in fibrin formation. Platelets are cell-like anucleated fragments, found in the blood of all mammals, that also participate in blood coagulation. Interaction of fibrinogen with the Ilb/IIIa receptor site is known to be essential for normal platelet function.
  • platelets When a blood vessel is damaged by an injury or other causative factor, platelets adhere to the disrupted subendothethial surface. The adherent platelets subsequently release biologically active constituents and aggregate. Aggregation is initiated by the binding of agonists, such as thrombin, epinephrine, or ADP to specific platelet membrane receptors. Stimulation by agonists results in exposure of latent fibrinogen receptors on the platelet surface, and binding of fibrinogen to the glycoprotein Ilb/IIIa receptor complex.
  • agonists such as thrombin, epinephrine, or ADP
  • arginine- glycine-aspartic acid containing tripeptides are recognized by at least one member of a family of structurally related receptors, integrins, which are heterodimeric proteins with two membrane-spanning subunits.
  • integrins which are heterodimeric proteins with two membrane-spanning subunits. The authors state that the conformation of the tripeptide sequence in the individual proteins may be critical to recognition specificity.
  • Ruggeri et al. Proc. Nat'l Acad. Sci. U.S.A., 83, 5708- 5712 ( 1986) explore a series of synthetic peptides designed in lengths to 16 residues, that contain RGD and a valine attached to the aspartic acid residue of RGD that inhibit fibrinogen binding to platelets. See also Koczewiak et al., Biochem. 23, 1767-1774 (1984); Ginsberg et al., J. Biol. Chem. 260(7), 3931-3936 (1985); and Haverstick et al., Blood 66(4), 946-952 (1985). Other inhibitors are disclosed in Eur. Pat. App. Nos. 275,748 and 298,820.
  • Ilb/IIIa complex This polypeptide contains 49 amino acids and has the RGD subunit and various disulfide bridges.
  • Gan et al. J. Biol. Chem., 263, 19827-19832 (1988).
  • Dennis et ai Proc. Nat'l Acad. Sci. USA, 87, 2471-2475 (1989).
  • these snake venom factors also have high affinity for other members of the adhesive protein receptor family including the vitronectin and fibronectin receptors so are not selective for the gp Ilb/IIIa complex.
  • 5,037,808 discloses the use of indolyl platelet-aggregation inhibitors which are believed to act by antagonizing interactions between fibrinogen and/or extracellular matrix proteins and the platelet gp Ilb/IIIa receptor.
  • U.S. Patent No. 5,037,808 discloses guanidino peptide mimetic compounds that retain an Asp residue which inhibit platelet aggregation.
  • WO9014103 describes the use of antibody-poly-peptide conjugates wherein said polypeptides contain the Arg-Gly-Asp (RGD) sequence.
  • W091 11458 discloses the use of large cyclic peptides containing RGD flanked by proline residues which are platelet
  • WO9101331 discloses small cyclic platelet aggregation inhibitors which are synthetic cyclic pentapeptides
  • U.S. Patent No. 5,051,405 also discloses the use of peptides and pseudopeptides such as N-amidino-piperidine-3-carboxylglycyl-L- aspartyl-L-valine that inhibit platelet aggregation and thrombus formation in mammalian blood.
  • EP 445 796 discloses linear compounds which can include internal piperazinyl or piperidinyl derivatives.
  • EP437 367 discloses linear polypeptide fibrinogen receptor antagonists.
  • U.S. Patent No. 5,256,812 discloses compounds of the R 1 -A-(W) a -X- (CH 2 ) b -(Y) c -B-Z-COOR wherein R 1 is a guandidino or amidino moiety and A and B are chosen from specific monosubstituted aryl or
  • a number of very serious diseases and disorders involve hyperthrombotic complications which lead to intravascular thrombi and emboli.
  • Myocardial infarction, stroke, phlebitis and a number of other serious conditions create the need for novel and effective fibrinogen receptor antagonists.
  • Fibrinogen receptor antagonists of this invention have the general formula:
  • variable groups are defined in detail below.
  • Compounds of the invention are useful for inhibiting the binding of fibrinogen to blood platelets and for inhibiting the
  • Combination therapies are also described which employ the instant compounds with other active agents such as a thrombolytic agent, an anticoagulant agent, and/or an antiplatelet agent.
  • a further object of this invention is to provide pharmaceutical compositions which are useful in the above-described methods. Further objects of this invention will be apparent from the disclosure herein.
  • the present invention provides compounds having the formula I
  • X is heterocycle
  • heterocycle is selected from:
  • ( 1 ) a five or six membered saturated, partially unsaturated or aromatic ring which consists of carbon atoms and one, two or three heteroatoms selected from the group -O-, -N-, -N(R 1 )- and -S-, wherein one of the carbon atoms may be substituted with a member selected from R 1 a and -NHR 1 , (2) an eight to ten membered bicyclic ring system which is saturated, or completely or partially unsaturated, and which consists of carbon atoms and one, two or three heteroatoms selected from the group -O-, -N-, -N(R 1 )- and -S-, wherein one of the carbon atoms may be substituted with a member selected from R 1a and -NHR 1 ,
  • A is a bond between X and Y or is selected from:
  • Y is selected from:
  • Z is selected from aryl and heterocycle; aryl is a 5- or 6-membered aromatic ring system which is unsubstituted or mono-, di- or tri-substituted with R 2 ;
  • n is an integer selected from 0 and 1;
  • R 1 and R 3 are independently selected at each occurrence from:
  • R 1a is independently selected at each occurrence from:
  • R 2 is independently selected at each occurrence from:
  • R 4 is selected from
  • D is selected from -SO 2 - and -C(O)-;
  • R 5 is selected from:
  • R 6 is selected from:
  • X-A- together represent a group selected from:
  • n is an integer selected from 2, 3, 4, and 5;
  • Q is selected from -N(R 1 )-, -S- and -O-;
  • Y is selected from:
  • R 1 a which consists of carbon atoms and one, two or three heteroatoms selected from the group -O-, -N-, -N(R 1 )- and -S-, and which may be fused to a benzene ring to form a bicyclic structure, for example,
  • aryl is a 5- or 6-membered aromatic carbon ring which is unsubstituted or mono-, di- or tri-substituted with R 2 ;
  • R 1 is independently selected at each occurrence from -H, C 1 - 10 alkyl, C 3-8 cycloalkyl-, aryl-C 0-8 alkyl- and hydroxy-C 0 -6 alkyl-;
  • R 1 a is independently selected at each occurrence from -H, halogen,
  • R 2 is independently selected at each occurrence from -H, halogen,
  • R 3 is independently selected at each occurrence from -H, -C 1 -10 alkyl
  • R 5 is selected from:
  • D is selected from -SO 2 - and -C(O)-;
  • R 6 is selected from:
  • heterocycle is selected from a five or six membered saturated, partially unsaturated or aromatic ring which is unsubstituted, or
  • R 1 a monosubstituted or disubstituted with R 1 a , and which consists of carbon atoms and one or two heteroatoms selected from the group -O-, -N-, -N(R 1 )- and -S-; and wherein the remaining variables are as defined above in formula I.
  • R 1 a monosubstituted or disubstituted with R 1 a , and which consists of carbon atoms and one or two heteroatoms selected from the group -O-, -N-, -N(R 1 )- and -S-; and wherein the remaining variables are as defined above in formula I.
  • Q is selected form -NH-, -O- and -S-;
  • Y is selected from:
  • Z is selected from:
  • R 1 is independently selected at each occurrence from -H and
  • R 1 a is independently selected at each occurrence from -H, halogen and -C 1 - 10 alkyl;
  • R 2 is independently selected at each occurrence from -H, halogen and -C 1 -10 alkyl
  • R 3 is independently selected at each occurrence from -H and
  • R 5 is selected from:
  • D is selected from -SO 2 - and -C(O)-; and R 6 is selected from:
  • heterocycle is selected from a five or six membered saturated, partially unsaturated or aromatic ring which is unsubstituted, or
  • R 1 a monosubstituted or disubstituted with R 1 a , and which consists of carbon atoms and one or two heteroatoms selected from the group -O-, -N-, -N(R 1 )- and -S-; and any remaining variables are as defined in formula II.
  • Y is selected from:
  • Z is selected from:
  • R 1 is independently selected at each occurrence from -H and
  • R 1a is independently selected at each occurrence from -H, halogen and -C 1-10 alkyl
  • R 2 is independently selected at each occurrence from -H, halogen and
  • R 3 is independently selected at each occurrence from -H and
  • R 5 is selected from:
  • D is selected from -SO 2 - and -C(O)-;
  • R 6 is selected from:
  • heterocycle is selected from a five or six membered saturated, partially unsaturated or aromatic ring which is unsubstituted, or
  • R 1 a monosubstituted or disubstituted with R 1 a , and which consists of carbon atoms and one or two heteroatoms selected from the group -O-, -N-, -N(R 1 )- and -S-; and the remaining variables are as defined in formula II.
  • Y is selected from -C(O)-N(R 1 )- and -N(R 1 )-C(O)-;
  • R 1 is independently selected at each occurrence from -H and
  • R 1a is independently selected at each occurrence from -H, halogen and -C 1-10 alkyl
  • R 2 is independently selected at each occurrence from -H, halogen and
  • R 3 is independently selected at each occurrence from -H and
  • R 5 is selected from:
  • D is selected from -SO 2 - and -C(O)-;
  • R 6 is selected from:
  • heterocycle is selected from a five or six membered saturated, partially unsaturated or aromatic ring which is unsubstituted, or
  • R 1 a monosubstituted or disubstituted with R 1 a , and which consists of carbon atoms and one or two heteroatoms selected from the group -O-, -N-, -N(R 1 )- and -S-;
  • Y is selected from -C(O)-NH- and -NH-C(O)-; and R 6 is selected from (1) unsubstituted, mono and disubstituted phenyl, (2) methyl, (3) benzyl wherein the aryl portion may be unsubstituted, mono or di-substituted, and (4) thienyl; and any remaining variables are as defined in formula IV.
  • a second class of the instant embodiments are compounds of formulas I, II, III , and IV wherein Y is -NH-C(O)-.
  • Compounds in this class are exemplified, but not limited to, those of formula VI as defined in Table II .
  • any substituent e.g., R 1 , R 2 , etc.
  • its definition on each occurrence is independent of its definition at any other occurrence.
  • combinations of substitutents and/or variables are permissible only if such combinations result in stable compounds.
  • alkyl is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, e.g., methyl (Me), ethyl (Et), propyl (Pr), butyl (Bu), pentyl, hexyl, heptyl, octyl, and the isomers thereof such as isopropyl (i-Pr), isobutyl (i-Bu), secbutyl (s-Bu), tertbutyl (t-Bu), isopentyl, isohexyl and the like.
  • cycloalkyl is intended to include cyclized alkyl chains having the specified number of carbon atoms, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • Alkoxy or "alkyloxy” represents an alkyl group having the indicated number of carbon atoms attached through an oxygen bridge, e.g., methoxy, ethoxy, propyloxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, t-butoxy and the like.
  • the specified number of carbon atoms in the appropriate groups described herein may include a zero in the range, e.g., C 0 -6 or C 0-8 When a zero is in the specified range, it means that a bond is present in place of that carbon group.
  • halo or halogen is meant to include fluoro, chloro, bromo and iodo.
  • oxy means an oxygen (O) atom.
  • aryl is defined above in the definition of Formula I; unsubstituted, mono-, di- and tri-substituted phenyl (Ph) is preferred.
  • heteroaryl is defined above in the definition of Formula I.
  • the term heteroaryl encompasses a five or six- membered heteroaryl ring as defined in formula I fused to a benzene, pyridine or pyrimidine ring.
  • heteroaryl groups include pyrrolyl, triazolyl, pyrazolyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, furanyl, pyranyl, thienyl, oxazolyl, isooxazolyl, thiazolyl, indolyl, benzimidazolyl, benzofuranyl, benzopyranyl, benzothienyl, quinolyl, isoquinolyl and the like.
  • heteroaryl ring may be attached within structural Formula I at any heteroatom or a carbon atom in the ring which results in the creation of a stable structure.
  • Preferred heteroaryl groups include pyridyl, thiazolyl, oxazolyl, thienyl, indolyl, benzofuranyl, and benzothienyl.
  • C 0 -6 alkylaryl as used herein includes an alkyl group as defined above bonded to an aryl group as defined above.
  • the C 0 -6 designation refers to the alkyl component of the alkylaryl unit.
  • Examples of C 0-8 alkylaryl include phenyl-, benzyl-, fluorobenzyl-, chlorobenzyl-, phenylethyl-, phenylpropyl-, fluorophenylethyl-, and chlorophenylethyl-.
  • C 0 -6 alkylheterocycle as used herein includes an alkyl group as defined above bonded to a heterocycle group as defined above.
  • the C 0-8 designation refers to the alkyl component of the alkylheterocycle unit.
  • Examples of C 0 -6 alkylheterocycle include thienyl-, thienylmethyl-, thienylethyl-, and thienylpropyl-.
  • Amino acids suitable for compounds of the present invention include naturally occurring L- or D-amino acids, for example, those naturally occurring L-amino acids present in humans, e.g., protein amino acids, including L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamine, L-glutamic acid, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L- proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine, and those naturally occurring D-amino acids which are non-protein amino acids, such as those found, for example, in antibiotic substances produced by bacteria and fungi, including D-valine, D-asparagine, D- glutamate, D-ornithine, D-phenylalan
  • salts shall mean non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
  • Representative salts include the following salts: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methyl
  • Prodrugs such as ester derivatives of described compounds, are compound derivatives which, when absorbed into the bloodstream of a warm-blooded animal, anabolize or cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.
  • the compounds of the present invention are chiral and the present compounds may occur as racemates, racemic mixtures and as individual diasteriomers or enantiomers with all such isomeric forms being included within the scope of this invention.
  • crystalline forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention.
  • some of the compounds of the instant invention may form solvates with water or common organic solvents. Such solvates and hydrates, as well as anhydrous compositions, are encompassed within the scope of this invention.
  • terapéuticaally effective amount shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease being treated.
  • mamal includes humans.
  • anti-coagulant shall include heparin, and warfarin.
  • thrombolytic agent shall include agents such as streptokinase and tissue plasminogen activator.
  • platelet anti- aggregation agent shall include agents such as aspirin and
  • the compounds of the present invention can be administered in such oral forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions.
  • intravenous bolus or infusion
  • intraperitoneal subcutaneous
  • intramusculsar form all using forms well known to those of ordinary skill in the pharmaceutical arts.
  • An effective but non-toxic amount of the compound desired can be any effective but non-toxic amount of the compound desired.
  • Compounds of the invention may be administered to patients where prevention of thrombosis by inhibiting binding of fibrinogen to the platelet membrane glycoprotein complex Ilb/II Ia receptor is desired. They are useful in surgery on peripheral arteries (arterial grafts, carotid endarterectomy) and in cardiovascular surgery where manipulation of arteries and organs, and/or the interaction of platelets with artificial surfaces, leads to platelet aggregation and consumption.
  • the aggregated platelets may form thrombi and
  • thromboemboli Compounds of this invention may be administered to these surgical patients to prevent the formation of thrombi and
  • Extracorporeal circulation is routinely used for cardiovascular surgery in order to oxygenate blood. Platelets adhere to surfaces of the extracorporeal circuit. Adhesion is dependent on the interaction between gp Ilb/IIIa on the platelet membranes and
  • the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed.
  • Oral dosages of the present invention when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day and preferably 0.01-100 mg/kg/day and most preferably 0.01 -20 mg/kg/day.
  • oral dosages for an adult patient are, for example, 1 mg, 10 mg or 100 mg.
  • the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion.
  • compounds of the present invention may be
  • preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art.
  • the dosage administration will, or course, be continuous rather that intermittent throughout the dosage regime.
  • the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as
  • carrier materials suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with convention pharmaceutical practices.
  • a therapuetically effective amount of a compound of formula I can be used for the preparation of a medicament useful for inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, or preventing thrombus or embolus formation in a mammal.
  • the medicament may be comprised of from 1 mg to 100 mgs of a compound of formula I, or more particularly, it may contain 1 mg, 10 mgs, 50 mgs, or 100 mgs of said compound.
  • Therapeutically effective amounts of a compound of formula I together with another active agent such as an anticoagulation agent or a thrombolytic agent can be used for the preparation of a medicament useful for inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, or preventing thrombus or embolus formation in a mammal.
  • active agents include plasminogen activators or streptokinase, heparin, aspirin, warfarin, ticlopidine and/or clopidogrel.
  • the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, distintegrating agents and coloring agents can also be incorporated into the mixture.
  • suitable binders, lubricants, distintegrating agents and coloring agents can also be incorporated into the mixture.
  • Suitable binders include starch, gelatin, natural sugars such as glucose or beta- lactose, corn-sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch methyl cellulose, agar, bentonite, xanthan gum and the like.
  • the compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
  • Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • the compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhy droxy- ethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.
  • the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
  • a drug for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
  • the compounds of the present invention can also be co- administered with suitable anticoagulation agents or thrombolytic agents such as plasminogen activators or streptokinase in the treatment of various vascular pathologies. They may also be combined with heparin, aspirin, warfarin, ticlopidine and/or clopidogrel. Coadministration includes administration together at essentially the same time in a single dosage form or in separate dosage forms, or each agent administered at separately staggered times in order to achieve beneficial thrombosis prevention or thrombolysis.
  • the compounds of the present invention can be prepared readily according to the following Schemes and Examples or modifications thereof using readily available starting materials, reagents and conventional synthesis procedures.
  • TBAF tetrabutylammonium fluoride
  • DEAD diethyl azodicarboxylate
  • PPh3 triphenyl phosphine
  • BOP Benzotriazol-1 -yloxytris(dimethylamino)phosphonium, hexafluorophosphate
  • NMM N-methyl morpholine
  • NMP N-methyl pyrrolidine
  • Oxone potassium peroxymonosulfate
  • Step 1 4-[3-(N-Boc-Piperidin-4-yl)propyloxylbenzaldehyde (1-3)
  • Step 2 N-[(3-(N-Boc-Piperidin-4-yl)propyloxy)phen-4-yl- methyl]glycine methyl ester ( 1 -5)
  • Step 3 N-[(3-(N-Boc-Piperidin-4-yl)pro ⁇ yloxy)phen-4-yl)- methyl]-N'-phenylsulfonyl glycine methyl ester (1 -6)
  • Step 4 N-[(3-(N-Boc-Piperidin-4-yl)propyloxy)phen-4-yl-methyl]- N'-phenylsulfonyl glycine (1-7)
  • ester 1-6 900 mg, 1.61 mmol
  • 1N NaOH (2 ml) and EtOH 5 ml
  • the reaction mixture was then acidified with 10% KHSO 4 , followed by extraction with EtOAc.
  • the organic portion was washed with brine, dried (MgSO 4 ) and concentrated to give the carboxylic acid 1-7 as a white solid.
  • Step 5 N-[(3-(Piperidin-4-yl)propyloxy)phen-4-yl-methyl]-N'- phenylsulfonyl glycine (1 -8)
  • Step 3 6-Formyl-N-[(N-Boc-piperidin-4-yl)ethyI]-3,4- dihydroisoquinolin-1 -one (2-5)
  • Step 4 N-(N-[(N-Boc-Piperidin-4-yl)ethyl]-3,4-dihydro- isoquinolin-1-one-6-yl-methyl)glycine methyl ester (2-6)
  • 4A molecular sieves (3.60 g)
  • Step 5 N-(N-[(N-Boc-Piperidin-4-yl)ethyl]3,4-dihydro- isoquinolin-1 -one-6-yl-methyl)-N'-phenylsulfonyI glycine methyl ester (2-7)
  • Step 6 N-(N-[(N-Boc-Piperidin-4-yl)ethyl]-3,4-dihydro- isoquinolin-1-one-6-yl-methyl)-N'-phenylsulfonyl glycine
  • ester 2-7 600 mg, 1.00 mmol
  • 1 N NaOH 2.0 ml
  • EtOH 5 ml
  • the reaction mixture was then acidified with 10% KHSO 4 followed by extraction with EtOAc.
  • the organic portion was washed with brine, dried (MgSO 4 ) and concentrated to give acid 2-8 as a white solid.
  • Step 7 N-(N-[(Piperidin-4-yl)ethyl]-3,4-dihydroisoquinolin-1-one-
  • the yellow solid was dissolved ethanol (200 mL) and shaken under an atmosphere of hydrogen gas at 50 psi in the presence of 0.8 g of 5% Pd/C for 18 h at RT.
  • the product solution was filtered through a pad of Celite, and the filtrate was concentrated under vacuum to give 2 as pink solid.
  • Step 2 4-[4-(4-tert-Butyloxycarbonyl-piperazin-1 -yl)phenylamino- carbonyl]-nitrobenze (3-4)
  • the resultant 4-nitrobenzoyl chloride (3-3) was dissolved in dichloro- methane (25 mL) and was added dropwisely to a cold (0°C) solution of aniline 3-2 (6.12 g, 22.1 mmol) and DMAP (135 mg) in a mixture of dichloromethane (30 mL) and pyridine (4.5 mL) over a period of 30 min.
  • the resultant slurry was diluted with dichloromethane (60 mL) and stirred at 0°C for 1 h.
  • the product mixture was further diluted with dichloromethane (600 mL), washed successively with sat. aq.
  • Step 4 N- ⁇ 4-14-(Piperazin-1-yl)phenylaminocarbonyl]phenyl ⁇ -N- phenyl-sulfonylglycine (3-6a)
  • Step 1 N-Benzylsulfonyl-4-[4-(4-tert-butyloxycarbonyl-piperazin-
  • Step 2 N- ⁇ 4-[4-(Piperazin-1 -yl)phenylaminocarbonyl]phenyl ⁇ -N- benzyl-sulfonylglvcine (3-6b)
  • Step 2 N- ⁇ 4-[4-(Piperazin-1-yl)phenylaminocarbonyl]phenyl ⁇ -N- methylsulfonylglycine (3-6c)
  • Step 1 N-4-bromo-phenylsulfonyl-4-[4-(4-tert-butyloxycarbonyl- piperazin-1-yl)-phenylamino-carbonyl]-aniline (3-5d)
  • Step 2 N- ⁇ 4-[4-(piperazin-1-yl)phenylaminocarbonyllphenyl ⁇ -N- 4-bromo-phenyl-sulfonylglycine (3-6d)
  • Step 1 N-4-nitrophenyl-N-phenylsulfonylglycine ethyl ester (4-8a)
  • Step 2 N- ⁇ 4-[4-(4-tert-Butyloxycarbonylpiperazin-1 - yl)phenylcarbonyl-amino]phenyl ⁇ -N-phenylsulfonylglycine ethyl ester (4-10a)
  • dichloromethane 25 mL and DMF (3 drops) at RT was treated with oxalyl chloride (0.43 mL, 4.9 mmol) over a period of 10 min.
  • the resultant solution was stirred at RT for 1 h, and concentrated under vacuum. The residue was dissolved in toluene and concentrated to remove residual oxalyl chloride.
  • the resultant acid chloride 4-9 was redissolved in dichloromethane (5 mL), and added to a cold (0°C) solution the above aniline (1.1 g, 3.3 mmol) and DMAP (0.48 g, 3.9 mmol) in dichloromethane (25 mL).
  • Step 3 N- ⁇ 4-[4-(Piperazin-1-yl)phenylcarbonylamino]phenyl ⁇ -N- phenyl-sulfonylglvcine (4-11a)
  • aq. sodium hydroxide (0.85 mL, 1 M, 1.7 mmol) was added.
  • the resultant mixture was stirred at RT for 2 h.
  • the product mixture was concentrated, acidified, and extracted into dichloromethane. The combined organic extract were dried over sodium sulfate, filtered and concentrated under vacuum.
  • This product was prepared using 2-thiophene sulfonyl chloride in place of phenylsulfonyl chloride in Step 1.
  • This product was prepared using 3-fluorophenylsulfonyl chloride in place of phenylsulfonyl chloride in Step 1.
  • This product was prepared using 4-fluorophenylsulfonyI chloride in place of phenylsulfonyl chloride in Step 1..
  • This product was prepared using trifluoromethanesulfonic anhydride and tert-butyl bromoacetate in place of phenylsulfonyl chloride and ethylbromo acetate, respectively, in Step 1.
  • This product was prepared using (1S)-(-)-10- camphorsulfonyl chloride in place of phenylsulfonyl chloride in Step 1..
  • Step 1 N-4-Nitrophenyl-N-benzoylglycine ethyl ester (5- 13a)
  • Step 2 N- ⁇ 4-[4-(4-tert-Butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonyl-amino]phenyl ⁇ -N-benzoylglycine ethyl ester (5 -14a)
  • Step 3 N- ⁇ 4-[4-(Piperazin-1-yl)phenylcarbonylamino]phenyl ⁇ -N- benzoyl-glycine (5-15a)
  • Step 1 N-4-Nitrophenyl-N-2-fluorobenzoyl-glycine ethyl ester (5- 13b)
  • Step 2 N- ⁇ 4-[4-(4-tert-Butyloxycarbonyl-piperazin-1-yl)- phenylcarbonyl-amino]phenyl ⁇ -N-2-fluorobenzoylglycine ethyl ester (5-14b)
  • Step 3 N- ⁇ 4-[4-(Piperazin-1-yl)phenyIcarbonylaminolphenyl ⁇ -N-
  • Step 1 N-4-Nitrophenyl-N-3-fluorobenzoylglycine ethyl ester (5-13c)
  • Step 2 N- ⁇ 4-[4-(4-tert-Butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonyl-amino]phenyl ⁇ -N-3-fluorobenzoylglycine ethyl ester (5-14c)
  • Step 3 N- ⁇ 4-[4-(piperazin-1-yl)phenylcarbonylamino]phenyl ⁇ -N-
  • Step 1 N-4-Nitrophenyl-N-4-fluorobenzoylglvcine ethyl ester (5-13d) Following the procedure described for 5-13a, but
  • Step 2 N- ⁇ 4-[ 4-(4-tert -Butyloxycarbonyl-piperazin-1-yl)- phenylcarbonyl-aminolphenyl ⁇ -N-4-fluorobenzoylglycine ethyl ester (5-14d)
  • Step 3 N- ⁇ 4-[4-(Piperazin-1 -yl)phenylcarbonylamino]phenyl ⁇
  • N-4-fluoro-benzoylglycine Following the procedure described for 4-1 1a. but substituting N- ⁇ 4-[4-(4-tert -butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonylamino]phenyl ⁇ -N-4-fluorobenzoyl-glycine ethyl ester (5-14d) for N- ⁇ 4-[4-(4-tert -butyloxycarbonyl-piperazin- 1-yl)- phenylcarbonylamino]phenyl ⁇ -N-phenylsulfonylglycine ethyl ester (4-10a), 5-15d was prepared.
  • Step 1 N-4-Nitrophenyl-N-picolinoyl-glycine ethyl ester (5-13d)
  • Step 2 N- ⁇ 4-[4-(4-tert-Butyloxycarbonyl-piperazin-1-yl)- phenylcarbonyl-amino]phenyl ⁇ -N-picolinoylglycine ethyl ester (5-14e)
  • Step 3 N- ⁇ 4-[4-(Piperazin-1 -yl)phenylcarbonylaminojphenyl ⁇ -
  • Step 1 N-4-Nitrophenyl-N-nicotinoyl-glycine ethyl ester (5-13f)
  • Step 2 N- ⁇ 4-[4-(4-tert- Butyloxycarbonyl-piperazin-1-yl)- phenylcarbonyl aminojphenyl ⁇ -N-nicotinoylglycine ethyl ester (5-14f)
  • Step 3 N- ⁇ 4-[4-(Piperazin-1-yl)phenylcarbonylamino]phenyl ⁇ -N- nicotinoyl-glycine (5-15f)
  • Step 1 N-4-Nitrophenyl-N-isonicotinoyl-glycine ethyl ester (5- 13g) Following the procedure described for 5-13a, but substituting isonicotinoyl chloride hydrochloride for benzoyl chloride, 5-13g was prepared.
  • Step 2 N-(4-[4-(4-tert -Butyloxycarbonyl-piperazin-1-yl)- phenylcarbonyl-amino]phenyl ⁇ -N-isonicotinoylglycine ethyl ester (5-14 g)
  • Step 3 N- ⁇ 4-[4-(Piperazin-1 -yl)phenylcarbonylaminolphenyl ⁇ -N- isonicotin-oyl-glycine (5-15g)
  • Step 1 N-4-Nitrophenyl-N-acetyl-glycine ethyl ester (5-13h)
  • Step 2 N- ⁇ 4-[4-(4-tert -Butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonyl-amino]phenyl ⁇ -N-acetylglycine ethyl ester
  • Step 3 N- ⁇ 4-[4-(Piperazin-1-yl)phenylcarbonyl mino]phenyl ⁇ -N- acetyl-glycine (5-15h)
  • Step 1 N-4-Nitrophenyl-N-cyclopropanecarboxylglycine ethyl ester (5-13i)
  • Step 2 N- ⁇ 4-[4-(4-tert-Butyloxycarbonyl-piperazin-1 -yl)- phenyIcarbonyl-amino]phenyl ⁇ -N-cyclopropane- carboxylglycine ethyl ester (5-14i)
  • Step 3 N- ⁇ 4-[4-(Piperazin-1-yl)phenylcarbonylamino]phenyl ⁇ -N- cyclopropanecarboxylglycine (5-15i)
  • Step 1 N-4-Nitrophenyl-N-benzyloxyacetyl-glycine ethyl ester (5-13j)
  • Step 2 N- ⁇ 4-[4-(4-tert -Butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonyl-aminolphenyl ⁇ -N-benzyloxyacetylglycine ethyl ester (5-14j)
  • Step 3 N- ⁇ 4-[4-(Piperazin-1-yl)phenyIcarbonylamino]phenyl ⁇ -N- benzyloxy-acetylglycine (5-15j)
  • Step 1 N-3-Methyl-4-nitrophenyl-N-benzoyl-glycine ethyl ester (5-131)
  • Step 2 N- ⁇ 4-[4-(4-tert-Butyloxycarbonyl-piperazin- 1 -yl)- phenylcarbonyl-aminol-3-methyl-phenyl ⁇ -N- benzoylglycine ethyl ester (5-141)
  • Step 3 N- ⁇ 4-[4-(Piperazin-1 -yl)phenylcarbonylamino]-3-methyl- phenyl ⁇ -N-2-benzoylglycine (5-151)
  • Step 1 N-2-Methyl-4-nitrophenyl-N-benzoyl-glycine ethyl ester (5-13m)
  • Step 2 N- ⁇ 4-[4-(4-tert-Butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonyl-amino]-2-methyl-phenyl ⁇ -N- benzoylglycine ethyl ester (5-14m)
  • Step 3 N- ⁇ 4-[4-(Piperazin-1-yl)phenyIcarbonyla mino]-2-memy phenyl ⁇ -N-2-benzoylglycine (5- 15m)
  • Step 1 N- ⁇ 4-[4-(4-tert-Butyloxycarbonyl-piperazin-1-yl)-3- methylphenyl-carbonylaminol-phenyl ⁇ -N-benzoylglycine ethyl ester (5-14n)
  • Step 2 N- ⁇ 4-[4-(Piperazin-1-yl)-3-methyl-phenylcarbonylaminol- phenyl )-N-benzoylglycine (5-15n)
  • Step 1 N- ⁇ 4-[4-(4-tert -Butyloxycarbonyl-piperazin-1-yl)-2- methylphenyl-carbonylamino]-phenyl ⁇ -N-benzoylglycine ethyl ester (5-14o)
  • Step 2 N- ⁇ 4-[4-(Piperazin-1 -yl)-2-methylphenylcarbonylamino]- phenyl ⁇ -N-benzoylglycine (5-15o)
  • Step 1 9-H-2-(1 ,1-Dimethylethoxycarbonyl)-7-bromo ⁇ -carboline
  • Step 2 9-H-2-(1 ,1-Dimethylethoxycarbonyl)- ⁇ -carbolin-7-yl
  • Step 3 N- ⁇ 4-[9-Boc- ⁇ -carbolme-7-yl)carbonylamino]phenyl ⁇ -N- phenyl-sulfonyl glycine (6-4)
  • Step 1 4-(4-Pyridyl)phenylcarboxylate (7-2)
  • HOAc/MeOH was treated with 250 mg PtO 2 and hydrogenated at 50 psi for 4 hr.
  • the solution was filtered through Solka Floe, evaporated and azeotroped with heptane to remove excess HOAc.
  • the intermediate amino acid acetic acid salt was obtained as a white solid.
  • Step 3 Ethyl 2-(1 -phenylsulfonamido-4-(4-(N-(1,1- dimethylethoxycarbonyl)-piperidin-4-yl)phenyl- carboxamide)-phenyl)acetate (7-4)
  • Step 4 N- ⁇ 4-[4-N-Boc-piperidin-4-yl)phenylcarboxylamino]- phenyl ⁇ -N-phenylsulfonylglycine (7-5)
  • Step 5 N- ⁇ 4-[4-Piperidm-4-yl)phenylcarbonylamino]phenyl ⁇ -N- phenyl-sulfonylglycine (7-6)
  • Step 1 4-(Pyridyl)piperidin-4-yl-carboxylic acid (8-1 )
  • Ethyl isonipecotate (6.0 g, 38.66 mmol), 4-chloropyridine hydrochloride (5.9 g, 38.66 mmol) and N-methylmorpholine (9.3 mL, 85.0 mmol) were dissolved in N-methylpyrrolidinone (50 mL) and the resulting solution heated at 100° for 48 h.
  • the solution was
  • Step 2 N- ⁇ 4-[N-(4-Pyridyl)-piperidinyl-4-carbonylamino ⁇ phenyl ⁇ - N-phenyl-sulfonyl-glycine methyl ester (8-2)
  • Step 1 N-4-(4-tert-Butyloxycarbonylpiperaziny-1-y)-benzoyl]-5- nitro-indoline (9-2)
  • Step 2 N-[4-(1 -tert-Butyloxycarbonylpiperaziny-1 -y)benzoyl]-5- phenyl-sulfonylamino-indoline (9-3)
  • Step 3 N- ⁇ N-[4-(4-tert-Butyloxycarbonylpiperaziny-1-yl)- benzoyn-5-indolinyl ⁇ -N-phenylsufonyl-glycine (9-4)
  • Step 3 N- ⁇ 2-[4-(4-tert-Butyloxycarbonylpiperazin-yl)- phenylamino-carbonyl]thien-5-yl ⁇ -N-phenylsulfonyl- glvcine methyl ester (10-4)
  • Step 1 6-Nitro-3,4-dihydroquinolin-2-(1H)-one (1 1 -2)
  • Step 3 6-[4-(4-tert-Butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonylaminol-1-carbomethoxymethyI-3,4- dihydroquinolin-2-(1H)-one (11 -4)
  • Step 4 6-[4-(4-Piperazin-1-yl)-phenylcarbonylamino]-1 - carbohydroxymethyl-3.4-dihvdroquinolin-2-(l H)-one (1 1 -5) Following the procedure described for 4-11 a, but substituting 6-[4-(4-tert -butyloxycarbonyl-piperazin-1 -yl)- pheny Icarbony lamino]- 1 -carbomethoxy-methyl-3 , 4-dihydroquinolin-2- (1H)-one (1 1-4) for 4- 10a, 1 1-5 was prepared.
  • Tablet Preparation Tablets containing 25.0, 50.0, and 100.0 mg., respectively, of the active compound p) from Table I are prepared as illustrated below:
  • Intravenous formulations An intravenous dosage form of the above-indicated active compound is prepared as follows:
  • the active compound is dissolved at room temperature in a previously prepared solution of sodium chloride, citric acid, and sodium citrate in Water for Injection (USP, see page 1636 of United States Pharmacopeia/National Formulary for 1995, published by United States Pharmacopeial Convention, Inc., Rockville, Maryland, copyright 1994.
  • Compounds of the invention may be administered to patients where inhibition of human or mammalian platelet aggregation or adhesion is desired.
  • Compounds of the invention are useful in inhibiting platelet aggregation and thus, they may find utility in surgery on peripheral arteries (arterial grafts, carotid endaterectomy) and in cardiovascular surgery where manipulation of arteries and organs, and/or the interation of platelets with artificial surfaces, leads to platelet aggregation and consumption.
  • the aggregated platelets may form thrombi and
  • thromboemboli Compounds of the invention may be administered to these surgical patients to prevent the formation of thrombi and

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Fibrinogen receptor antagonists of the general formula (I): X-A-Y-Z-B, and which includes, for example, the compounds of formula (IV), are useful for inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, and preventing thrombus or embolus formation.

Description

TITLE OF THE INVENTION
FIBRINOGEN RECEPTOR ANTAGONISTS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to U.S. provisional application No. 60/012,380, filed February 28, 1996.
BACKGROUND OF THE INVENTION
The invention relates generally to modulating cell adhesion and to inhibiting the binding of fibrinogen and other proteins to blood platelets, and inhibiting the aggregation of blood platelets specifically to the gp Ilb/IIIa fibrinogen receptor site. Fibrinogen is a glycoprotein present in blood plasma that participates in platelet aggregation and in fibrin formation. Platelets are cell-like anucleated fragments, found in the blood of all mammals, that also participate in blood coagulation. Interaction of fibrinogen with the Ilb/IIIa receptor site is known to be essential for normal platelet function.
When a blood vessel is damaged by an injury or other causative factor, platelets adhere to the disrupted subendothethial surface. The adherent platelets subsequently release biologically active constituents and aggregate. Aggregation is initiated by the binding of agonists, such as thrombin, epinephrine, or ADP to specific platelet membrane receptors. Stimulation by agonists results in exposure of latent fibrinogen receptors on the platelet surface, and binding of fibrinogen to the glycoprotein Ilb/IIIa receptor complex.
Attempts have been made to use natural products and synthetic peptides to determine the mechanism of adhesion and platelet aggregation. For example, Rouslahti and Pierschbacher in Science, 238, 491 -497 (1987), describe adhesive proteins such as fibronectin, vitronectin, osteopontin, collagens, thrombospondin, fibrinogen, and von Willebrand factor that are present in extracellular matrices and in blood. The proteins contain the tripeptide arginine-glycine-aspartic acid (RGD) as their glycoprotein Ilb/IIIa recognition site. These arginine- glycine-aspartic acid containing tripeptides are recognized by at least one member of a family of structurally related receptors, integrins, which are heterodimeric proteins with two membrane-spanning subunits. The authors state that the conformation of the tripeptide sequence in the individual proteins may be critical to recognition specificity.
Cheresh in Proc. Nat'l Acad. Sci. U.S.A., 84, 6471 -6475, ( 1987), describes an Arg-Gly-Asp directed adhesion receptor expressed by human endothethial cells that is structurally similar to the Ilb/IIIa complex on platelets but is antigenically and functionally distinct. This receptor is directly involved in endothelial cell attachment to fibrinogen, von Willebrand factor, and vitronectin.
Pierschbacher and Rouslahti, in J. of Biol. Chem., 262, (36), 17294- 17298 (1987) hypothesized that the Arg-Gly-Asp sequence alone would be a sufficient signal for receptor recognition and binding and that, therefore, the conformation of the tri-peptide sequence would be determinative. Various synthetic peptides were produced and the authors concluded that the sterochemical conformation of Arg-Gly-Asp as influenced by enantiomeric substitutions or additions to this sequence significantly influenced receptor-ligand interaction. The authors further showed that cyclization of a decapeptide by forming a disulfide bridge between non-terminal residues Pen and Cys, rendered the peptide much less effective at inhibiting attachment to fibronectin.
In Proc. Nat'l Acad. Sci. U.S.A., 81 , 5985-5988 (1984), the same authors describe tetrapeptide variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Peptides having a tetrapeptide recognition site are described in U.S. Pat. Nos. 4,589,881 and 4,614,517. A number of large polypeptide fragments in the cell- binding domain of fibronectin have cell-attachment activity. For example, see U.S. Pat. Nos. 4,517,686, 4,661 , 1 1 1 and U.S. Pat. No. 4,578,079.
Ruggeri et al., Proc. Nat'l Acad. Sci. U.S.A., 83, 5708- 5712 ( 1986) explore a series of synthetic peptides designed in lengths to 16 residues, that contain RGD and a valine attached to the aspartic acid residue of RGD that inhibit fibrinogen binding to platelets. See also Koczewiak et al., Biochem. 23, 1767-1774 (1984); Ginsberg et al., J. Biol. Chem. 260(7), 3931-3936 (1985); and Haverstick et al., Blood 66(4), 946-952 (1985). Other inhibitors are disclosed in Eur. Pat. App. Nos. 275,748 and 298,820.
A number of low molecular weight polypeptide factors have been isolated from snake venom. These factors apparently have high affinity for the gp Ilb/IIIa complex. For example, Huang et al., J. Biol Chem., 262, 16157-16163 (1987); Huang et al., Biochemistry, 28, 661 -666 (1989) describe the primary structure of the venom trigramin which is a 72 amino acid polypeptide that contains the RGD subunit. Echistatin is another compound which has high affinity for the gp
Ilb/IIIa complex. This polypeptide contains 49 amino acids and has the RGD subunit and various disulfide bridges. Gan et al., J. Biol. Chem., 263, 19827-19832 (1988). See also, Dennis et ai, Proc. Nat'l Acad. Sci. USA, 87, 2471-2475 (1989). However, these snake venom factors also have high affinity for other members of the adhesive protein receptor family including the vitronectin and fibronectin receptors so are not selective for the gp Ilb/IIIa complex.
While it is known that the tripeptide sequence Arg-Gly-Asp is present in certain polypeptides that can duplicate or inhibit the cell attachment-promoting effects of fibronectin and vitronectin, the tripeptide Arg-Gly-Asp has low activity. At present, there is little understanding of how other amino acids coupled to this sequence influence binding specificity. U.S. Patent No 5,023,233 discloses small cyclic hexapeptides which contain the sequence Arg-Gly-Asp and are useful platelet aggregation inhibitors. U.S. Patent No. 5,037,808 discloses the use of indolyl platelet-aggregation inhibitors which are believed to act by antagonizing interactions between fibrinogen and/or extracellular matrix proteins and the platelet gp Ilb/IIIa receptor. U.S. Patent No. 5,037,808 discloses guanidino peptide mimetic compounds that retain an Asp residue which inhibit platelet aggregation.
WO9014103 describes the use of antibody-poly-peptide conjugates wherein said polypeptides contain the Arg-Gly-Asp (RGD) sequence. W091 11458 discloses the use of large cyclic peptides containing RGD flanked by proline residues which are platelet
aggregation inhibitors. WO9101331 discloses small cyclic platelet aggregation inhibitors which are synthetic cyclic pentapeptides
containing the tripeptide sequence Arg-Gly-Asp and a thioether linkage in the cycle. U.S. Patent No. 5,051,405 also discloses the use of peptides and pseudopeptides such as N-amidino-piperidine-3-carboxylglycyl-L- aspartyl-L-valine that inhibit platelet aggregation and thrombus formation in mammalian blood. EP 445 796 discloses linear compounds which can include internal piperazinyl or piperidinyl derivatives.
EP437 367 discloses linear polypeptide fibrinogen receptor antagonists. U.S. Patent No. 5,256,812 discloses compounds of the R 1 -A-(W)a-X- (CH2)b-(Y)c -B-Z-COOR wherein R1 is a guandidino or amidino moiety and A and B are chosen from specific monosubstituted aryl or
heterocyclic moieties.
While a multitude of compounds or peptide analogs believed to inhibit platelet aggregation by inhibiting binding to a blood platelet by fibrinogen are known, the present invention provides novel fibrinogen receptor antagonists that have significant binding activity and are, therefore, useful for the reasons stated herein. A number of very serious diseases and disorders involve hyperthrombotic complications which lead to intravascular thrombi and emboli. Myocardial infarction, stroke, phlebitis and a number of other serious conditions create the need for novel and effective fibrinogen receptor antagonists.
SUMMARY OF THE INVENTION
One object of this invention is to provide novel compounds which are active as fibrinogen receptor antagonists. Fibrinogen receptor antagonists of this invention have the general formula:
X-A-Y-Z-B I,
and include, for example, the compounds of formula
Figure imgf000007_0001
wherein the variable groups are defined in detail below.
Compounds of the invention are useful for inhibiting the binding of fibrinogen to blood platelets and for inhibiting the
aggregation of blood platelets. Therefore, it is another object of this invention to provide methods of inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, or preventing thrombus or embolus formation in a mammal, preferably a human, using the instant compounds. Combination therapies are also described which employ the instant compounds with other active agents such as a thrombolytic agent, an anticoagulant agent, and/or an antiplatelet agent. A further object of this invention is to provide pharmaceutical compositions which are useful in the above-described methods. Further objects of this invention will be apparent from the disclosure herein.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides compounds having the formula I
X-A-Y-Z-B I and the pharmaceutically acceptable salts, esters, solvates and
stereoisomers thereof wherein:
X is heterocycle;
heterocycle is selected from:
( 1 ) a five or six membered saturated, partially unsaturated or aromatic ring which consists of carbon atoms and one, two or three heteroatoms selected from the group -O-, -N-, -N(R 1)- and -S-, wherein one of the carbon atoms may be substituted with a member selected from R 1 a and -NHR 1 , (2) an eight to ten membered bicyclic ring system which is saturated, or completely or partially unsaturated, and which consists of carbon atoms and one, two or three heteroatoms selected from the group -O-, -N-, -N(R1)- and -S-, wherein one of the carbon atoms may be substituted with a member selected from R1a and -NHR1,
(3) a thirteen to fourteen membered tricyclic ring system
which is saturated, or completely or partially unsaturated, and which consists of carbon atoms and one, two or three heteroatoms selected from the group -O-, -N-, -N(R1)- and
-S- , wherein one of the carbon atoms may be substituted with a member selected from R1a and -NHR1;
A is a bond between X and Y or is selected from:
( 1 ) phenyl substituted with R1a,
(2) -N(R1)-, and
Figure imgf000008_0001
Y is selected from:
(1) -C1-8 alkyl--
(2) -C4-10 cycloalkyl-,
(3) -C0-8 alkyl-NR1-CO-C0-8 alkyl-,
(4) -C0-8 alkyl-CONR1-C0-8 alkyl-,
(5) -C0-8 alkyl-O-C0-8 alkyl-,
(6) -C0-8 alkyl-SOp-C0-8 alkyl-,
(7) -(CH2)0-8-aryl-(CH2)0-8-,
(8) (-CH2)0-6-aryl-SOp-
(9) -(CH2)0-8-aryl-CO-(CH2)0-8-,
(10) -(CH2)0-6-aryl-SOp-(CH2)0-6-,
(11) -(CH2)0-6-NR1-(CH2)0-6-,
(12) -(CH2)0-6-aryl-CH(OH)-(CH2)0-6-,
(13) -(CH2)0-8-aryl-CONH-(CH2)0-8-, (14) -C0-8 alkyl-SOp-NR1 -C0-8 alkyl-,
(15) -C0-8 alkyl-CO-C0-8 alkyl-, and
(16) -C0-8 aIkyl-CH(OH)-C0-8-alkyl-; p is an integer selected from 0, 1 and 2;
Z is selected from aryl and heterocycle; aryl is a 5- or 6-membered aromatic ring system which is unsubstituted or mono-, di- or tri-substituted with R2;
B is
Figure imgf000009_0001
wherein m is an integer selected from 0 and 1;
R1 and R3 are independently selected at each occurrence from:
(1) hydrogen,
(2) C1-10 alkyl-,
(3) C3-8 cycloalkyl-,
(4) aryI-C0-8 alkyl-,
(5) amino-C0-8 alkyl-,
(6) C1-6 alkylamino-C0-8 alkyl-,
(7) C1-6 dialkylamino-C0-8 alkyl-,
(8) C1-3 acylamino-C0-8 alkyl-,
(9) C1-4alkoxy-C0-6alkyl-,
(10) -C0-6 alkyl-CO2H,
(11) - C1-6 alkyl-CO2C1-3 alkyl,
(12) -O-C1-6 alkyl-CO2H and
(13) hydroxy-C1-6 alkyl-;
R1a is independently selected at each occurrence from:
(1) hydrogen, (2) halogen,
(3) C1-10 alkyl-,
(4) C3-8 cycloalkyl-,
(5) aryl-C0-8 alkyl-,
(6) amino-C0-8 alkyl-,
(7) C1-6 alkylamino-C0-8 alkyl-,
(8) C1-6 dialkylamino-C0-8 alkyl-,
(9) C1-3 acylamino-C0-8 alkyl-,
(10) C1-4alkoxy-C1-6 alkyl-,
(11) -C1-6 alkyl-CO2H,
(12) -C1-6 alkyl-CO2 C1-3 alkyl,
(13) -O-C1-6 alkyl-CO2H,
(14) hydroxy C1-6 alkyl and
(15) oxo (=O);
R2 is independently selected at each occurrence from:
(1) hydrogen,
(2) halogen,
(3) C1-10 alkyl-,
(4) C3-8 cycloalkyl-,
(5) aryl-C0-8 alkyl-,
(6) amino-C0-8 alkyl-,
(7) C1-6 alkylamino-C0-8 alkyl-,
(8) C1-6 dialkylamino-C0-8 alkyl-,
(9) C1-3 acylamino-C0-8 alkyl-,
(10) C1-4 alkoxy-C0-6 alkyl-,
(11) -C1-6 alkyl-CO2H,
(12) -C1-6 alky 1-CO2C1-3 alkyl,
(13) -O-C1-6 alkyl-CO2H, and
(14) hydroxy C1-6 alkyl;
R4 is selected from
(1) -(CH2)p-D-R6 wherein p is defined above,
Figure imgf000011_0001
(4) when Z is unsubstituted or substituted phenyl and m is zero, R4 together with the nitrogen to which it is attached can form a bicyclic structure with Z (phenyl) as follows:
Figure imgf000011_0002
D is selected from -SO2- and -C(O)-;
R5 is selected from:
(1) -OH,
(2) C1 -8 alkyloxy-,
(3) aryl C0 -6 alkyloxy-,
(4) C1 -8 alkylcarbonyloxy C1 -4 alkyloxy-,
(5) aryl C1 -8 alkylcarbonyloxy C1 -4 alkyloxy-, and
(6) L- or D-amino acid joined by an amide linkage and wherein the carboxylic acid moiety of said amino acid is as the free acid or is esterified by C1 -6 alkyl; and
R6 is selected from:
(1 ) -C1 -6alkyl, unsusbstituted, mono- or di -substituted with R1 a, (6) -(C0 -6alkyl)aryl, wherein the alkyl group is unsusbstituted, mono- or di -substituted with R1 a,
(3) -(C0 -6alkyl)heterocycle, wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1 a, (4) -NR1( C1 -6alkyl), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(5) -NR1(C0 -6alkylaryl), wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1 a,
(6) -NR1(C0 -6alkylheterocycle), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(7) -C3-6 cycloalkyl, and
(8) -CF3.
In a one embodiment of this invention are compounds of formula I which have the particular formula II:
Figure imgf000012_0001
and the pharmaceutically acceptable salts, solvates and stereoisomers thereof wherein:
X-A- together represent a group selected from:
Figure imgf000013_0001
n is an integer selected from 2, 3, 4, and 5;
Q is selected from -N(R1)-, -S- and -O-;
Y is selected from:
(1) -C0-8 alkyl-NR1-CO-C0-8 alkyl-,
(2) -C0-8 alkyl-CONR1-C0-8 alkyl-,
(3) -C0-8 alkyl-O-C0-8 alkyl-,
(4) -C0-8 alkyl-SOp-C0-8 alkyl-,
(5) -(CH2)0-6-NR1-(CH2)0-6-,
(6) -C0-8 alkyl-SOp-NR1 -C0-8 alkyl-,
(7) -C0-8 alkyl-CO-C0-8 alkyl-, and
(8) -C0-8 alkyl-CH(OH)-C0-8-alkyl-; p is an integer selected from 0, 1 and 2;
Z is selected from
(1 ) aryl and
(2) a five or six membered saturated, partially unsaturated or aromatic heterocyclic ring which is unsubstituted, or monosubstituted or disubstituted with R1 a, which consists of carbon atoms and one, two or three heteroatoms selected from the group -O-, -N-, -N(R 1)- and -S-, and which may be fused to a benzene ring to form a bicyclic structure, for example,
Figure imgf000014_0001
aryl is a 5- or 6-membered aromatic carbon ring which is unsubstituted or mono-, di- or tri-substituted with R2;
R 1 is independently selected at each occurrence from -H, C1 - 10 alkyl, C3-8 cycloalkyl-, aryl-C0-8 alkyl- and hydroxy-C0 -6 alkyl-;
R1 a is independently selected at each occurrence from -H, halogen,
-C1 - 10 alkyl, C3-8 cycloalkyl-, aryl-C0-8 alkyl-, and
amino-C0-8 alkyl-;
R2 is independently selected at each occurrence from -H, halogen,
-C1 -10 alkyl, C3-8 cycloalkyl-, aryl-C0-8 alkyl- and
C1 -4 alkoxy-C0-8 alkyl-;
R3 is independently selected at each occurrence from -H, -C1 -10 alkyl,
C3-8 cycloalkyl- and aryl-C0-8 alkyl-;
R5 is selected from:
(1 ) -OH,
(2) C1 -8 alkyloxy-,
(3) aryl-C0 -6 alkyloxy-,
(4) C1 -8 alkylcarbonyloxy-C1 -4 alkyloxy-, and
(5) aryl-C1 -8 alkylcarbonyloxy-C1 -4 alkyloxy-;
D is selected from -SO2- and -C(O)-; and
R6 is selected from:
( 1 ) -C1 -6alkyl, unsusbstituted, mono- or di-substituted with R1 a,
(2) -(C0 -6alkyl)aryl, wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a, (3) -(C0 -6alkyl)heterocycle, wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(4) -NRl(C1 -6alkyl), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(5) -NRl(C0 -6alkylaryl), wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1 a,
(6) -NRl(C0 -6alkylheterocycle), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(7) -C3-6 cycloalkyl,
(8) -CF3,
Figure imgf000015_0001
(1 1 ) when Z is unsubstituted or substituted phenyl, D-R6
together with the nitrogen to which it is attached can form a bicyclic structure with Z (phenyl) as follows:
Figure imgf000015_0002
heterocycle is selected from a five or six membered saturated, partially unsaturated or aromatic ring which is unsubstituted, or
monosubstituted or disubstituted with R1 a, and which consists of carbon atoms and one or two heteroatoms selected from the group -O-, -N-, -N(R1 )- and -S-; and wherein the remaining variables are as defined above in formula I. In a second, further embodiment of this invention are compounds of formula II and the pharmaceutically acceptable salts, solvates and stereoisomers thereof wherein X-A- together represent a group selected from:
Figure imgf000016_0001
and the remaining variable are as defined above in formula II.
In a third, further embodiment of this invention are compounds of formula II and the pharmaceutically acceptable salts, solvates and stereoisomers thereof wherein X-A- together represent a group selected from:
Figure imgf000016_0002
and the pharmaceutically acceptable salts, hydrates and stereoisomers thereof wherein:
Q is selected form -NH-, -O- and -S-;
Y is selected from:
(1 ) -NR1 -CO-, (2) -CONR1-,
(3) -O-,
(4) -SOp-,
(5) -NR1-,
(6) -SOp-NR1-,
(7) -CO-, and
(8) -CH(OH)-; p is an integer selected from 0, 1 and 2;
Z is selected from:
(1 ) phenyl,
(2) phenyl which is mono-, di- or tri -substituted with R2,
(3) thienyl,
Figure imgf000017_0001
R1 is independently selected at each occurrence from -H and
-C1 - 10 alkyl;
R1 a is independently selected at each occurrence from -H, halogen and -C1 - 10 alkyl;
R2 is independently selected at each occurrence from -H, halogen and -C1 -10 alkyl;
R3 is independently selected at each occurrence from -H and
-C1 -10 alkyl;
R5 is selected from:
(1) -OH,
(2) C1 -8 alkyloxy-,
(3) aryl-C0 -6 alkyloxy-,
(4) C1 -8 alkylcarbonyloxy-C1 -4 alkyloxy-, and
(5) aryl-C1 -8 alkylcarbonyloxy-C1 -4 alkyloxy-;
D is selected from -SO2- and -C(O)-; and R6 is selected from:
(1 ) -C1 -6alkyl, unsusbstituted, mono- or di-substituted with R1 a,
(2) -(C0 -6alkyl)aryl, wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(3) -(C0 -6alkyl)heterocycle, wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1 a,
(4) -NR4 (C1 -6alkyl), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(5) -NR1(C0 -6alkylaryl), wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1 a,
(6) -NR1(C0 -6alkylheterocycle), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(7) -C3-6 cycloalkyl,
(8) -CF3,
Figure imgf000018_0001
(1 1 ) when Z is unsubstituted or substituted phenyl, D-R6
together with the nitrogen to which it is attached can form a bicyclic structure with Z (phenyl) as follows:
Figure imgf000018_0002
heterocycle is selected from a five or six membered saturated, partially unsaturated or aromatic ring which is unsubstituted, or
monosubstituted or disubstituted with R1 a, and which consists of carbon atoms and one or two heteroatoms selected from the group -O-, -N-, -N(R1)- and -S-; and any remaining variables are as defined in formula II.
In a fourth, further embodiment of this invention are compounds of formula II having the particular formula III
Figure imgf000019_0001
and the pharmaceutically acceptable salts, solvates and stereoisomers thereof wherein:
Y is selected from:
(1) -NR1-CO-,
(2) -CONR1-,
(3) -O-,
(4) -SOp-,
(5) -NR1 -,
(6) -SOp-NR1-,
(7) -CO-, and
(8) -CH(OH)-; p is an integer selected from 0, 1 and 2;
Z is selected from:
(1) phenyl,
(2) phenyl which is mono-, di- or tri -substituted with R2,
(3) thienyl,
Figure imgf000020_0001
R1 is independently selected at each occurrence from -H and
-C1-10 alkyl;
R1a is independently selected at each occurrence from -H, halogen and -C1-10 alkyl;
R2 is independently selected at each occurrence from -H, halogen and
-C1- 10 alkyl;
R3 is independently selected at each occurrence from -H and
-C1-10 alkyl;
R5 is selected from:
(1) -OH,
(2) C1-8 alkyloxy-,
(3) aryl-C1-6 alkyloxy-,
(4) C1 -8 alky lcarbonyloxy-C1-4 alkyloxy-, and
(5) aryl-C1-8 alkylcarbonyloxy-C1-4 alkyloxy-;
D is selected from -SO2- and -C(O)-; and
R6 is selected from:
(1) -C1-6alkyl, unsusbstituted, mono- or di-substituted with R1a,
(2) -(C1-6alkyl)aryl, wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1a,
(3) -(C1-6alkyl)heterocycle, wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1a, (4) -NR1(C1-6alkyl), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1a,
(5) -NR1(C1-6alkylaryl), wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1a,
(6) -NR1(C1-6alkylheterocycle), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1a,
(7) -C3-6 cycloalkyl,
Figure imgf000021_0001
(11 ) when Z is unsubstituted or substituted phenyl, D-R6
together with the nitrogen to which it is attached can form a bicyclic structure with Z (phenyl) as follows:
Figure imgf000021_0002
heterocycle is selected from a five or six membered saturated, partially unsaturated or aromatic ring which is unsubstituted, or
monosubstituted or disubstituted with R1 a, and which consists of carbon atoms and one or two heteroatoms selected from the group -O-, -N-, -N(R1 )- and -S-; and the remaining variables are as defined in formula II.
In a fifth, further embodiment of this invention are compounds of formula III having the particular formula IV
Figure imgf000021_0003
and the pharmaceutically acceptable salts, solvates and stereoisomers thereof wherein:
Y is selected from -C(O)-N(R1)- and -N(R1)-C(O)-;
R1 is independently selected at each occurrence from -H and
-C1-10 alkyl;
R1a is independently selected at each occurrence from -H, halogen and -C1-10 alkyl;
R2 is independently selected at each occurrence from -H, halogen and
-C1-10 alkyl;
R3 is independently selected at each occurrence from -H and
-C1-10 alkyl;
R5 is selected from:
(1) -OH,
(2) C1-8 alkyloxy-,
(3) aryl-C1-6 alkyloxy-,
(4) C1-8 alkylcarbonyloxy-C1-4 alkyloxy-, and
(5) aryl-C1-8 alkylcarbonyloxy-C1-4 alkyloxy-;
D is selected from -SO2- and -C(O)-; and
R6 is selected from:
( 1 ) -C1 -6alkyl, unsusbstituted, mono- or di-substituted with R1a,
(2) -(C0 -6 alkyl)aryl, wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1a,
(3) -(C1-6alkyl)heterocycle, wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1a,
(4) -NRl(C1-6alkyl), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1a,
(5) -NR1(C1-6alkylaryl), wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1a, (6) -NR1(C1-6alkylheterocycle), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1a,
(7) -C3-6 cycloalkyl,
(8) -CF3,
Figure imgf000023_0001
(11) when Z is unsubstituted or substituted phenyl, D-R6
together with the nitrogen to which it is attached can form a bicyclic structure with Z (phenyl) as follows:
Figure imgf000023_0002
heterocycle is selected from a five or six membered saturated, partially unsaturated or aromatic ring which is unsubstituted, or
monosubstituted or disubstituted with R1 a, and which consists of carbon atoms and one or two heteroatoms selected from the group -O-, -N-, -N(R1)- and -S-;
and any remaining variables are as defined in formula IlI .
In a sixth, further embodiment of this invention are compounds of formula IV wherein Y is selected from -C(O)-NH- and -NH-C(O)-; and R6 is selected from (1) unsubstituted, mono and disubstituted phenyl, (2) methyl, (3) benzyl wherein the aryl portion may be unsubstituted, mono or di-substituted, and (4) thienyl; and any remaining variables are as defined in formula IV.
In one class of the instant six embodiments are compounds of formulas I, II, III, and IV as defined in the general definition wherein Y is -C(O)-NH-. Compounds in this class are exemplified, but not limited to, those of formula V as defined in Table I. The carbons around the phenyl rings in formula V have been arbitrarily numbered in order to clearly identify the substituent positions, where necessary.
Figure imgf000024_0001
Figure imgf000025_0002
In a second class of the instant embodiments are compounds of formulas I, II, III , and IV wherein Y is -NH-C(O)-. Compounds in this class are exemplified, but not limited to, those of formula VI as defined in Table II .
Figure imgf000025_0001
Figure imgf000026_0001
Additional examples of compounds within the scope of this invention are shown below but are not limited to, those of formula VII as defined in Table II l.
Figure imgf000027_0001
When any substituent (e.g., R 1 , R2, etc.) occurs more than one time in any constituent, its definition on each occurrence is independent of its definition at any other occurrence. Also, combinations of substitutents and/or variables are permissible only if such combinations result in stable compounds.
As used herein "alkyl" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, e.g., methyl (Me), ethyl (Et), propyl (Pr), butyl (Bu), pentyl, hexyl, heptyl, octyl, and the isomers thereof such as isopropyl (i-Pr), isobutyl (i-Bu), secbutyl (s-Bu), tertbutyl (t-Bu), isopentyl, isohexyl and the like. The term "cycloalkyl" is intended to include cyclized alkyl chains having the specified number of carbon atoms, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. "Alkoxy" or "alkyloxy" represents an alkyl group having the indicated number of carbon atoms attached through an oxygen bridge, e.g., methoxy, ethoxy, propyloxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, t-butoxy and the like.
The specified number of carbon atoms in the appropriate groups described herein may include a zero in the range, e.g., C0 -6 or C0-8 When a zero is in the specified range, it means that a bond is present in place of that carbon group.
The term halo or halogen is meant to include fluoro, chloro, bromo and iodo. The term "oxy" means an oxygen (O) atom.
The term "aryl" is defined above in the definition of Formula I; unsubstituted, mono-, di- and tri-substituted phenyl (Ph) is preferred.
The term heteroaryl is defined above in the definition of Formula I. The term heteroaryl encompasses a five or six- membered heteroaryl ring as defined in formula I fused to a benzene, pyridine or pyrimidine ring. Examples of heteroaryl groups include pyrrolyl, triazolyl, pyrazolyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, furanyl, pyranyl, thienyl, oxazolyl, isooxazolyl, thiazolyl, indolyl, benzimidazolyl, benzofuranyl, benzopyranyl, benzothienyl, quinolyl, isoquinolyl and the like. The heteroaryl ring may be attached within structural Formula I at any heteroatom or a carbon atom in the ring which results in the creation of a stable structure. Preferred heteroaryl groups include pyridyl, thiazolyl, oxazolyl, thienyl, indolyl, benzofuranyl, and benzothienyl.
The term "C0 -6 alkylaryl" as used herein includes an alkyl group as defined above bonded to an aryl group as defined above. The C0 -6 designation refers to the alkyl component of the alkylaryl unit. Examples of C0-8 alkylaryl include phenyl-, benzyl-, fluorobenzyl-, chlorobenzyl-, phenylethyl-, phenylpropyl-, fluorophenylethyl-, and chlorophenylethyl-.
The term "C0 -6 alkylheterocycle" as used herein includes an alkyl group as defined above bonded to a heterocycle group as defined above. The C0-8 designation refers to the alkyl component of the alkylheterocycle unit. Examples of C0 -6 alkylheterocycle include thienyl-, thienylmethyl-, thienylethyl-, and thienylpropyl-.
Amino acids suitable for compounds of the present invention include naturally occurring L- or D-amino acids, for example, those naturally occurring L-amino acids present in humans, e.g., protein amino acids, including L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamine, L-glutamic acid, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L- proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine, and those naturally occurring D-amino acids which are non-protein amino acids, such as those found, for example, in antibiotic substances produced by bacteria and fungi, including D-valine, D-asparagine, D- glutamate, D-ornithine, D-phenylalanine, D-leucine, D-cysteine, and D- aspartate. (see Zubay "BIOCHEMISTRY" Addison-Wesley Publishing Company, Inc. (Reading, MA) 1983 pp. 867-870 and Stryer
"BIOCHEMISTRY" W.H. Freeman and Company (New York, NY) 3rd Edition 1988 pp. 16-21).
The term "pharmaceutically acceptable salts" shall mean non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts include the following salts: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, pamaote, palmitate, panthothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, valerate.
Prodrugs, such as ester derivatives of described compounds, are compound derivatives which, when absorbed into the bloodstream of a warm-blooded animal, anabolize or cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.
The compounds of the present invention are chiral and the present compounds may occur as racemates, racemic mixtures and as individual diasteriomers or enantiomers with all such isomeric forms being included within the scope of this invention.
Furthermore, some of the crystalline forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds of the instant invention may form solvates with water or common organic solvents. Such solvates and hydrates, as well as anhydrous compositions, are encompassed within the scope of this invention.
The term "therapeutically effective amount" shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease being treated. The term "mammal" includes humans. The term "anti-coagulant" shall include heparin, and warfarin. The term "thrombolytic agent" shall include agents such as streptokinase and tissue plasminogen activator. The term "platelet anti- aggregation agent" shall include agents such as aspirin and
dipyridamole.
The compounds of the present invention can be administered in such oral forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions.
Likewise, they may be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramusculsar form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be
employed as an anti-aggregation agent.
Compounds of the invention may be administered to patients where prevention of thrombosis by inhibiting binding of fibrinogen to the platelet membrane glycoprotein complex Ilb/II Ia receptor is desired. They are useful in surgery on peripheral arteries (arterial grafts, carotid endarterectomy) and in cardiovascular surgery where manipulation of arteries and organs, and/or the interaction of platelets with artificial surfaces, leads to platelet aggregation and consumption. The aggregated platelets may form thrombi and
thromboemboli. Compounds of this invention may be administered to these surgical patients to prevent the formation of thrombi and
thromboemboli.
Extracorporeal circulation is routinely used for cardiovascular surgery in order to oxygenate blood. Platelets adhere to surfaces of the extracorporeal circuit. Adhesion is dependent on the interaction between gp Ilb/IIIa on the platelet membranes and
fibrinogen adsorbed to the surface of the circuit. (Gluszko et al., Amer. J. Physiol, 252(H), 615-621 (1987)). Platelets released from artificial surfaces show impaired hemostatic function. Compounds of the invention may be administered to prevent adhesion. Other applications of these compounds include prevention of platelet thrombosis, thromboembolism and reocclusion during and after thrombolytic therapy and prevention of platelet thrombosis, thromboembolism and reocclusion after angioplasty or coronary artery bypass procedures. They may also be used to prevent myocardial infarction.
The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or
veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.
Oral dosages of the present invention, when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day and preferably 0.01-100 mg/kg/day and most preferably 0.01 -20 mg/kg/day.
Typically, oral dosages for an adult patient are, for example, 1 mg, 10 mg or 100 mg. Intravenously, the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion. Advantageously, compounds of the present invention may be
administered in divided doses of two, three, or four times daily.
Furthermore, preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, or course, be continuous rather that intermittent throughout the dosage regime.
In the methods of the present invention, the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as
"carrier" materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with convention pharmaceutical practices. As such, a therapuetically effective amount of a compound of formula I can be used for the preparation of a medicament useful for inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, or preventing thrombus or embolus formation in a mammal. For example, the medicament may be comprised of from 1 mg to 100 mgs of a compound of formula I, or more particularly, it may contain 1 mg, 10 mgs, 50 mgs, or 100 mgs of said compound.
Therapeutically effective amounts of a compound of formula I together with another active agent such as an anticoagulation agent or a thrombolytic agent can be used for the preparation of a medicament useful for inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, or preventing thrombus or embolus formation in a mammal. Examples of other active agents which may be used include plasminogen activators or streptokinase, heparin, aspirin, warfarin, ticlopidine and/or clopidogrel.
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, distintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta- lactose, corn-sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch methyl cellulose, agar, bentonite, xanthan gum and the like.
The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhy droxy- ethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
The compounds of the present invention can also be co- administered with suitable anticoagulation agents or thrombolytic agents such as plasminogen activators or streptokinase in the treatment of various vascular pathologies. They may also be combined with heparin, aspirin, warfarin, ticlopidine and/or clopidogrel. Coadministration includes administration together at essentially the same time in a single dosage form or in separate dosage forms, or each agent administered at separately staggered times in order to achieve beneficial thrombosis prevention or thrombolysis. The compounds of the present invention can be prepared readily according to the following Schemes and Examples or modifications thereof using readily available starting materials, reagents and conventional synthesis procedures. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. The examples are not intended to be limitations on the scope of the instant invention in any way, and they should not be so construed. Furthermore, the compounds described in the following examples are not to be construed as forming the only genus that is considered as the invention, and any combination of the compounds or their moieties may itself form a genus. Specific definitions of variables in the Schemes are illustrative only, and are not intended to limit the procedures described, unless otherwise noted. All temperatures are degrees Celsius unless otherwise noted.
Some abbreviations used herein are as follows: TBAF is tetrabutylammonium fluoride; DEAD is diethyl azodicarboxylate; PPh3 is triphenyl phosphine. Many of the compounds described in the examples were analyzed by FAB mass spectroscopy (FABMS), and MS values are denoted.
In the schemes and examples below, various reagent symbols have the following meanings:
Ac: acyl (CH3-C(O)-)
BOC (or Boc): t-butyloxycarbonyl
BOC2O: di-t-butyl dicarbonate
BOP: Benzotriazol-1 -yloxytris(dimethylamino)phosphonium, hexafluorophosphate
Bn: benzyl
n-BuLi: n-butyllithium
t-BuLi: tert-butyl lithium
CBZ: Carbobenzyloxy
CH2CI2: Methylene chloride
CHCl3: chloroform
Pd-C: Palladium on activated carbon catalyst DMF: Dimethylformamide
DMSO: Dimethylsulfoxide
EDC: 1 -(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
EtOAc: ethyl acetate
EtOH: ethanol
HOAc: acetic acid
LDA: Lithium diisopropylamide
MeOH: methanol
NMM: N-methyl morpholine
NMP: N-methyl pyrrolidine
Oxone: potassium peroxymonosulfate
PYCLU: chloro N,N,N',N'-bis(pentamethylene)formamidinium hexafluorophosphate
RT: room temperature
TBDMS or TMS: t-butyldimethyl silyl
TFA: trifluoroacetic acid
THF: tetrahydrofuran;
TLC: thin layer chromatography
Figure imgf000037_0001
Figure imgf000038_0001
EXAMPLE 1
Step 1 : 4-[3-(N-Boc-Piperidin-4-yl)propyloxylbenzaldehyde (1-3)
A solution of 3-(N-Boc-piperidin-4-yl)propyl iodide 1-1 (5.0 g, 14.2 mmol) (preparation described in EP 478,328), 4- hydroxybenzaldehyde 1-2 (1.73 g, 14.2 mmol), Cs2CO3 (9.2 g, 28.4 mmol) and DMF (50 ml) was stirred at ambient temperature for 2.0 hours. The reaction mixture was diluted with ethyl acetate and then washed with H2O, sat. NaHCO3, 10% KHSO4, brine, dried (MgSO4) and concentrated. Flash chromatography (silica, 10% EtOAc/hexane) provided 1- 3 as a white solid.
TLC Rf 0.80 (silica, 40% EtOAc/hexane)
1H NMR (300 MHz, CDCI3) δ 9.88 (s, 1H), 7.83 (d, J=9Hz, 2H), 6.99 (d, J=9Hz, 2H), 4.1 1 (m, 2H), 4.04 (t, J=6Hz, 2H), 2.69 (bt, 2H), 1.84, (m, 2H), 1.69 (bd, 2H), 1.46 (m, 12H), 1.14 (m, 2H).
Step 2: N-[(3-(N-Boc-Piperidin-4-yl)propyloxy)phen-4-yl- methyl]glycine methyl ester ( 1 -5)
To a stirred suspension of 4Å molecular sieves (4 g) and
CH3OH (30 ml) was added NaOAc ( 1.18 g, 14.5 mmol), compound 1-3 (1.0 g, 2.89 mmol), amine 1-4 (363 mg, 2.89 mmol) and NaCNBH3 (546 mg, 8.67 mmol). After 18 h, the reaction mixture was filtered through a celite pad. The pH of the resulting solution was adjusted to ~2 by the dropwise addition of cone. HCl to decompose excess hydride. The pH was adjusted to ~12 by the addition of K2CO3. The mixture was extracted with EtOAc. The organic portion was washed with brine, dried (MgSO4) and concentrated. Flash chromatography (silica, 80% EtO Ac/provided) amine 1-5 as a colorless oil.
TLC Rf 0.32 (silica, EtO Ac)
1H NMR (300 MHz, CD3OD) δ 7.22 (d, J=9Hz, 2H), 6.85 (d, J=9Hz, 2H), 4.10 (bd, 2H), 3.94 (t, J=6Hz, 2H), 3.70 (m, 5H), 3.36 (s, 2H), 2.77 (m, 2H), 1.77 (m, 4H), 1.43 (m, 12H), 1.07 (m, 2H).
Step 3: N-[(3-(N-Boc-Piperidin-4-yl)proρyloxy)phen-4-yl)- methyl]-N'-phenylsulfonyl glycine methyl ester (1 -6)
To a stirred solution of amine 1-5 (900 mg, 2.15 mmol), pyridine (347 μl, 4.30 mmol) and CH2CI2 (20 ml) at 0°C was added phenylsulfonylchloride (300 μl, 2.37 mmol) followed by the removal of the cooling bath. After 18 h, the reaction was diluted with EtOAc and then washed with H2O, 10% KHSO4, brine, dried (MgSO4) and concentrated. Flash chromatography (silica, 20% EtOAc/hexane) gave ester 1-6 as a colorless oil.
TLF Rf 0.82 (silica, 50% EtOAc/hexane)
1 H NMR (300 MHz, CDCI3) δ 7.88 (d, J=9H, 2H), 7.56 (m, 3H), 7.14 (d, J=9Hz, 2H), 6.81 (d, J=9Hz, 2H), 4.43 (s, 2H), 4.12 (m, 2H), 3.91
(m, 4H), 3.53 (s, 3H), 2.68 (bt, 2H), 1.79 (m, 2H), 1.68 (bd, 2H), 1.46
(m, 12H), 1.10 (m, 2H).
Step 4: N-[(3-(N-Boc-Piperidin-4-yl)propyloxy)phen-4-yl-methyl]- N'-phenylsulfonyl glycine (1-7)
A solution of ester 1-6 (900 mg, 1.61 mmol), 1N NaOH (2 ml) and EtOH (5 ml) was stirred at ambient temperature for 30 minutes. The reaction mixture was then acidified with 10% KHSO4, followed by extraction with EtOAc. The organic portion was washed with brine, dried (MgSO4) and concentrated to give the carboxylic acid 1-7 as a white solid.
TLC Rf 0.48 (silica, 9:0.5:0.5 CH2Cl2/MeOH/AcOH)
1H NMR (300 MHz, CD3OD) δ 7.87 (d, J=8Hz, 2H), 7.59 (m, 3H), 7.09 (d, J=8Hz, 2H), 6.82 (d, J=9H, 2H), 4.41 (s, 2H), 4.04 (bd, 2H), 3.93 (t, J=6Hz, 2H), 3.84 (s, 2H), 2.76 (m, 2H), 1.79 (m, 4H), 1.44 (m, 12H), 1.04 (m, 2H).
Step 5: N-[(3-(Piperidin-4-yl)propyloxy)phen-4-yl-methyl]-N'- phenylsulfonyl glycine (1 -8)
A solution of acid 1-7 (400 mg, 0.7334 mmol), TFA (3 ml) and CH2CI2 (3 ml) was stirred at ambient temperature for 1.0 hour. The solution was concentrated and then azeotroped with toluene. Flash chromatography (silica, 20:1 :1 EtOH/NH4OH/H2O) furnished amine 1 -8 as a white solid.
TLC Rf 0.41 (silica, 20:1:1 EtOH/NH4OH/H2O)
1H NMR (300 MHz, NaOD/D2O) δ 7.79 (d, J=8Hz, 2H), 7.66 (d, J=7Hz, 1H), 7.56 (t, J=8Hz, 2H), 7.06 (d, J=8Hz, 2H), 8.45 (d, J=9Hz, 2H), 4.42 (s, 2H), 4.01 (t, J=8Hz, 2H), 3.76 (s, 2H), 2.91 (m, 2H), 2.47 (t, J=12Hz, 2H), 1.74 (m, 4H), 1.32 (m, 3H), 1.06 (m, 2H).
Figure imgf000041_0001
Figure imgf000042_0001
EXAMPLE 2
Step 1 : 6-Bromo-3,4-dihydroisoquinolin-1-one (2-2)
To a stirred solution of bromide 2-1 (20.0 g, 94.8 mmol), H2SO4 (25.4 ml) and benzene (130 ml) at ambient temperature was added NaN3 (8.88 g, 136.6 mmol) portionwise over a 30 minute period. After 1.0 hour, the reaction was diluted with EtOAc and then washed with H2O, brine, dried (MgSO4) and concentrated. Flash
chromatography (silica, 40% EtOAc/hexanes→ EtOAc) furnished bromide 2-2 as an orange solid.
TLC Rf 0.31
1H NMR (300 MHz, CDCI3) δ 7.93 (d, J=8Hz, 1H), 7.49 (d, J=8Hz, 1H), 7.40 (s, 1H), 6.32 (bs, 1H), 3.57 (m, 2H), 2.99 (t, J=7Hz, 2H). Step 2: 6-Bromo-N-[(N-Boc-ρiperidin-4-yl)ethyl]-3,4,- dihydroisoquinolin-1-one (2-4)
To a stirred solution of bromide 2-1 (1.33 g, 5.88 mmol) and DMF (30 ml) at -15°C was added NaN (TMS)2 (1.0 M/THF; 6.4 ml) dropwise over a 10 minute period. After 10 minutes, a solution of iodide 2-3 (2.0 g, 5.88 mmol) and DMF (4 ml) was added to the reaction mixture followed by the removal of the cooling bath. After 1.0 hour, the solution was diluted with EtOAc and then washed with 10% KHSO4, brine, dried (MgSO4) and concentrated. Flash
chromatography (silica, 50% EtOAc/hexanes) afforded bromide 2-4 as a colorless oil.
TLC Rf 0.23 (silica, 50% EtOAc/hexanes)
1H NMR (300 MHz, CDCI3) δ 7.93 (d, J=8Hz, 1H), 7.46 (d, J=8Hz, 1H), 7.35 (s, 1H), 4.12 (m, 2H), 3.56 (m, 4H), 2.97 (t, J=7Hz, 2H), 1.69 (m, 3H), 1.54 (m, 2H), 1.45 (s, 9H), 1.13 (m, 2H).
Step 3: 6-Formyl-N-[(N-Boc-piperidin-4-yl)ethyI]-3,4- dihydroisoquinolin-1 -one (2-5)
To a stirred solution of bromide 2-4 (1.90 g, 4.34 mmol), DMF (342 μl, 4.34 mmol) and THF (15 ml) at -78°C was added t-BuLi (1.7 M/pentane; 7.66 ml, 13.02 mmol) dropwise over a 5 minute period. After 1.0 hour, the reaction was quenched with AcOH. The solution was diluted with EtOAc and then washed with 10% KHSO4, sat.
NaHCO3, brine, dried (MgSO4) and concentrated. Flash
chromotography (silica, 30%→ 50% EtOAc/hexanes) gave aldehyde 2-5 as a colorless oil.
TLC Rf 0.13 (silica, 50% EtOAc/hexanes)
1H NMR (300 MHz, CDCI3) δ 10.06 (s, 1H), 8.24 (d, 8Hz, 1H), 7.84 (d, J=8Hz, 1H), 7.72 (s, 1H), 4.12 (m, 2H), 3.61 (m, 4H), 3.08 (t, J=7Hz, 2H), 2.69 (t, 13Hz, 2H), 1.75 (d, J=13Hz, 2H), 1.59 (m, 2H), 1.45 (s, 10H), 1.19 (m, 2H).
Step 4: N-(N-[(N-Boc-Piperidin-4-yl)ethyl]-3,4-dihydro- isoquinolin-1-one-6-yl-methyl)glycine methyl ester (2-6) To a stirred suspension of 4A molecular sieves (3.60 g) and
CH3OH (30 ml) was added NaOAc (1.06 g, 12.95 mmol), benzaldehyde 2-5 (1.0 g, 2.59 mmol), amine 1-4 (326 mg, 2.59 mmol) and NaCNBH3 (490 mg, 7.77 mmol). After 1.0 h, the reaction mixture was filtered through a celite pad. The pH of the resulting solution was adjusted to ~2 by the dropwise addition of 1N HCl. After 10 minutes, the pH was adjusted to ~12 by the addition of K2CO3. The mixture was extracted with EtOAc. The organic portion was washed with brine, dried
(MgSO4) and concentrated. Flash chromatography (silica, EtOAc) afforded amine 2-6 as a white solid.
TLC Rf 0.09 (silica, EtOAc)
1H NMR (300 MHz, CD3OD) 7.89 (d, J=8Hz, 1H), 7.33 (d, J=8Hz, 1H), 7.26 (s, 1H), 4.07 (m, 2H), 3.81 (s, 2H), 3.72 (s, 3H), 3.60 (m, 4H), 3.40 (s, 2H), 3.00 (t, J=7Hz, 2H), 2.73 (bt, 2H), 1.78 (bd, J=12Hz, 2H), 1.61 (m, 2H), 1.44 (s, 10H), 1.10 (m, 2H). Step 5: N-(N-[(N-Boc-Piperidin-4-yl)ethyl]3,4-dihydro- isoquinolin-1 -one-6-yl-methyl)-N'-phenylsulfonyI glycine methyl ester (2-7)
To a stirred solution of amine 2-6 (800 mg, 1.75 mmol), NMM (488 μl, 3.50 mmol) and CH2CI2 (10 ml) at 0°C was added benzenesulfonyl chloride (243 μl, 1.93 mmol) in a single portion followed by the removal of the cooling bath. After 48 h, the
heterogeneous mixture was diluted with EtOAc and then washed with H2O, sat. NaHCO3, 10% KHSO4, brine, dried (MgSO4) and
concentrated. Flash chromatography (silica, 50%→ 60%
EtOAc/hexanes) furnished ester 2-7 as a white solid.
TLC Rf 0.16 (silica, 50% EtOAc/hexanes)
1H NMR (300 MHz, CD3OD) δ 7.86 (m, 3H), 7.65 (d, J=7Hz, 1H), 7.59 (d, J=9Hz, 2H), 7.20 (d, J=8Hz, 1H), 7.14 (s, 1H), 4.52 (s, 2H), 4.07 (m, 2H), 3.98 (s, 2H), 3.59 (m, 4H), 3.52 (s, 3H), 2.94 (t, J=8Hz, 2H), 2.76 (m, 2H), 1.78 (bd, J=13Hz, 2H), 1.57 (m, 2H), 1.44 (s, 10H), 1.15 (m, 2H).
Step 6: N-(N-[(N-Boc-Piperidin-4-yl)ethyl]-3,4-dihydro- isoquinolin-1-one-6-yl-methyl)-N'-phenylsulfonyl glycine
(2-8)
A solution of ester 2-7 (600 mg, 1.00 mmol), 1N NaOH (2.0 ml) and EtOH (5 ml) was stirred at ambient temperature for 1.5 hours. The reaction mixture was then acidified with 10% KHSO4 followed by extraction with EtOAc. The organic portion was washed with brine, dried (MgSO4) and concentrated to give acid 2-8 as a white solid.
1H NMR (300 MHz, CD3OD) δ 7.86 (m, 3H), 7.64 (d, J=7Hz, 1H), 7.57 (d, J=9Hz, 2H), 7.21 (d, J=8Hz, 1H), 7.13 (s, 1H), 4.54 (s, 2H), 4.04 (bd, J=11Hz, 2H), 3.93 (s, 2H), 3.59 (m, 4H), 2.94 (t, J=6Hz, 2H), 2.73 (m, 2H), 1.76 (bd, J=13Hz, 2H), 1.57 (m, 2H), 1.44 (s, 10H), 1.13 (m, 2H).
Figure imgf000046_0001
Step 7: N-(N-[(Piperidin-4-yl)ethyl]-3,4-dihydroisoquinolin-1-one-
6-yl-methyl)-N'-phenylsulfonyl glycine (2-9) EtOAc (8 ml) at 0°C was treated with HCl (g) until saturated. A suspension of acid 2-8 (300 mg, 0.5124 mmol) and EtOAc (2 ml) was added in a single portion. After 30 minutes, argon was bubbled through the solution. The solvent was removed in vacuo to give amine 2-9 as a white solid.
1H NMR (300 MHz, D2O) δ 7.79 (d, J=8Hz, 2H), 7.74 (m, 2H), 7.57 (m, 2H), 7.18 (d, J=8Hz, 1H), 7.01 (s, 1H), 4.46 (s, 2H), 4.08 (s, 2H), 3.56 (m, 4H), 3.42 (bd, J=14Hz, 2H), 2.96 (t, J=13Hz, 2H), 2.86 (t, J=7Hz, 2H), 2.03 (d, J=14Hz, 2H), 1.64 (m, 3H), 1.45 (m, 2H). EXAMPLE 2A
N-(N-[(Piperidin-4-yl)emyl]-3,4-dihydroisoquinolin-1-one-6-yl- methyl)-N'-phenylsulfonyl glycine methyl ester hvdrochloride (2-10)
EtOAc (8 ml) at 0°C was treated with HCl (g) until saturated. A suspension of ester 2-1 (300 mg, 0.5004 mmol) and EtOAc
(2 ml) was added in a single portion. After 30 minutes, argon was bubbled through the solution. The solvent was removed in vacuo to give amine 2-10 as a white solid.
1H NMR (D2O) δ 7.82 (d, J=8Hz, 2H), 7.74 (m, 2H), 7.60 (t, J=8Hz, 2H), 7.21 (d, J=8Hz, 1H), 7.07 (s, 1H), 4.47 (s, 2H), 4.14 (s, 2H), 3.56
(m, 7H), 3.42 (d, J=13Hz, 2H), 2.90 (m, 4H), 2.03 (d, J=14Hz, 2H),
1.65 (m, 3H), 1.45 (m, 2H).
Figure imgf000047_0001
Figure imgf000048_0001
EXAMPLE 3A
Step 1 : 4-(4-tert-Butyloxycarbonyl-piperazin-1-yl )aniline (3-2)
To a solution of 1 -(4-nitrophenyl)piperazine (3-1) (9.8 g, 47.29 mmol) and triethylamine (7.3 mL, 52.37 mmol) in dichloro- methane (175 mL) at RT, Boc2O (11.38 g, 52.14 mmol) was added portionwise. The resultant mixture was stirred at RT for 2 h. The product mixture was concentrated under vacuum, and the residue triturated with hexane (150 mL). The resultant yellow powder was obtained by filtration.
Without further purification, the yellow solid was dissolved ethanol (200 mL) and shaken under an atmosphere of hydrogen gas at 50 psi in the presence of 0.8 g of 5% Pd/C for 18 h at RT. The product solution was filtered through a pad of Celite, and the filtrate was concentrated under vacuum to give 2 as pink solid.
Step 2: 4-[4-(4-tert-Butyloxycarbonyl-piperazin-1 -yl)phenylamino- carbonyl]-nitrobenze (3-4)
To a suspension of 4-nitrobenzoic acid (4.06 g, 24.29 mmol) in dichloromethane (40 mL) and DMF (200 μL) at RT, oxalyl chloride (2.8 mL, 32 mmol) was added dropwise with a syringe pump over a period of 1 h. The resultant solution was stirred at RT for 0.5 h, and concentration under vacuum. The residue was dissolved in benzene and concentrated under vacuum to remove residual oxalyl chloride. The resultant 4-nitrobenzoyl chloride (3-3) was dissolved in dichloro- methane (25 mL) and was added dropwisely to a cold (0°C) solution of aniline 3-2 (6.12 g, 22.1 mmol) and DMAP (135 mg) in a mixture of dichloromethane (30 mL) and pyridine (4.5 mL) over a period of 30 min. The resultant slurry was diluted with dichloromethane (60 mL) and stirred at 0°C for 1 h. The product mixture was further diluted with dichloromethane (600 mL), washed successively with sat. aq.
sodium bicarbonate, sat aq. potassium hydrogen sulfate, water, and then brine until the aqueous extract was neutral. The dichloromethane solution was loaded directly onto a column of silica gel and the column eluted with ethyl acetate. Collection and concentration of appropriate fractions provided the amide 3-4.
Step 3: N-Phenylsulfonyl-4-[4-(4-tert-butyloxycarbonyl-piperazin-
1 -yl)-phenylaminocarbonyllaniline (3-5a)
A suspension of the nitrobenzene 3-4 (6.9 g, 16.18 mmol) and 5% Pd/C (0.93 g) in ethanol (110 mL) was shaken under an atmosphere of hydrogen gas at 50 psi overnight at RT. The resultant mixture was filtered through a plug of Celite, and washed repetitively with methanol (500 mL). The filtrate was concentrated under vacuum. The residue was treated with toluene and concentrated under vacuum to remove residual alcohols. The resultant aniline (4.49 g, 11.32 mmol) was treated with phenylsulfonyl chloride (1.75 mL, 13.7 mmol) in pyridine (15 mL) at 100°C for 2 h. The resultant mixture was
concentrated under vacuum. The residue was dissolved in methanol and concentrated onto silica gel. The resultant solid was loaded onto a column of silica gel and eluted with 80% ethyl acetate in hexane.
Collection and concentration of appropriate fractions provided the sulfonamide 3-5a. Step 4: N-{4-14-(Piperazin-1-yl)phenylaminocarbonyl]phenyl}-N- phenyl-sulfonylglycine (3-6a)
To cold (0°C) solution of the sulfonamide 3-5a (2.02 g, 3.76 mmol) in DMF (15 mL), sodium hydride (96 mg, 3.99 mmol) was added. The mixture was stirred at RT for 15 min. The resultant solution was cooled back to 0°C, and methyl bromoacetate (380 μL, 4.01 mmol) was added, and stirred at RT overnight. The product mixture was concentrated under vacuum, and the residue dissolved in ethyl acetate. The organic fraction was washed successively with aq. sodium bicarbonate and brine, dried over magnesium sulfate, filtered and concentrated under vacuum. The residue was subjected to column chromatography on silica gel eluting with 60% ethyl acetate in hexane. Collection and concentration of appropriate fractions provided N-4- [4(4-tert -butyloxycarbonyl-piperazin-1-yl)phenylaminocarbonyl]phenyl- N-phenylsulfonylglycine methyl ester.
To a solution of the glycine methyl ester (430 mg, 0.7 mmol) in a mixture of methanol (10 mL) and ethanol (3 mL) at RT, aq. sodium hydroxide (2.8 mL, 1 M, 2.8 mmol) was added. The resultant mixture was stirred at RT for 5 h. The product mixture was
concentrated, acidified with 1 M hydrochloric acid, and extracted with ethyl acetate (3 x 70 mL). The organic extracts were combined, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was dissolved in dichloromethane (7 mL) and treated with trifluoroacetic acid (3 mL) at RT for 2.5 h. The product solution was concentrated under vacuum. The residue was dissolved in water, frozen and lyophilized overnight to provide the sulfonylglycine 3 -6a as a white fluffy solid.
1 H NMR (CD3OD): δ 7.84 (2H, d, J=8.6Hz), 7.71 -7.49 (7H, m), 7.36
(2H, d, J=8.6Hz), 7.03 (2H, J=9.0 Hz), 4.51 (2H, s), 3.38 (8H, br s). Analysis calculated for C25H26N4O5S• 1.30 TFA•0.20 H2O
C, 51.28; H, 4.32; N, 8.67
Found: C, 51.29; H, 4.31 ; N, 8.90 EXAMPLE 3B
Step 1 : N-Benzylsulfonyl-4-[4-(4-tert-butyloxycarbonyl-piperazin-
1-yl)-phenylaminocarbonyl]-aniline (3-5b)
Following the procedure described for 3-5a, but substituting benzylsulfonyl chloride for phenylsulfonyl chloride, 3-5b was prepared.
Step 2: N-{4-[4-(Piperazin-1 -yl)phenylaminocarbonyl]phenyl }-N- benzyl-sulfonylglvcine (3-6b)
Following the procedure described for 3-6a, but starting with N-benzylsulfonyl-4-[4-(4-tert -butyloxycarbonyl-piperazin-1-yl)- phenylaminocarbonyljaniline (3-5b), 3-6b was prepared.
Analysis calculated for C26H28N4O5S• 1.40 TFA•0.44 H2O
C, 51.16; H, 4.51; N, 8.29
Found: C, 51.16; H, 4.51; N, 8.55
EXAMPLE 3C Step 1 : N-Methylsulfonyl-4-[4-(4-tert-butyloxycarbonyl-piperazin-
1 -yl)-phenylaminocarbonyllaniline (3-5c)
Following the procedure described for 3-5a, but substituting methanesulfonyl chloride for phenylsulfonyl chloride, 3-5c was prepared.
Step 2: N-{4-[4-(Piperazin-1-yl)phenylaminocarbonyl]phenyl }-N- methylsulfonylglycine (3-6c)
Following the procedure described for 3-6a, but starting with N-methylsulfonyl-4-[4-(t-tert-butyloxycarbonyl-piperazin-1 - yl)phenylaminocarbonyl]aniline (3-5c), 3-6c was prepared.
Analysis calculated for C20H24N4O5S• 1.48 TFA•0.14 H2O
C, 45.67; N, 4.30; N, 9.28
Found: C, 45.67; H, 4.30; N, 9.49 EXAMPLE 3D
Step 1 : N-4-bromo-phenylsulfonyl-4-[4-(4-tert-butyloxycarbonyl- piperazin-1-yl)-phenylamino-carbonyl]-aniline (3-5d)
Following the procedure described for 3-5a, but
substituting 4-bromophenylsulfonyl chloride for phenylsulfonyl chloride, 3-5d was prepared.
Step 2: N-{4-[4-(piperazin-1-yl)phenylaminocarbonyllphenyl } -N- 4-bromo-phenyl-sulfonylglycine (3-6d)
Following the procedure described for 3-6a, but startiig with N-4-bromo-phenylsulfonyl-4-[4-(4-tert -butyloxycarbonyl- piperazin- 1 -yl)-phenylamino-carbonyl]-aniline (3-5d), 3-6d was prepared.
Analysis calculated for C25H25BrN4O5S•1.58 TFA•0.34 H2O
C, 44.52; H, 3.62; N, 7.37
Found: C, 44.51 ; H, 3.62; N, 7.50
Figure imgf000053_0001
SCHEME 4 CONTINUED wherein the precursors (4-8, 4-10) and the corresponding final products (4-1 1) have R and R1 defined as follows:
Figure imgf000054_0001
Step 1 : N-4-nitrophenyl-N-phenylsulfonylglycine ethyl ester (4-8a)
A solution of 4-nitroaniline (4-7) (13.8 g, 100 mmol) and phenylsulfonyl chloride (14 mL, 100 mmol) in pyridine (50 mL) was heated at 100°C for 2 h. The resultant solution was concentrated, and the residue dissolved in ethyl acetate. The organic extract was washed successively with 2 M hydrochloric acid, sat. aq. sodium bicarbonate brine, dried over magnesium sulfate, filtered and concentrated under vacuum. The residue was dissolved in a minimum amount of ethyl acetate with warning, and hexane added until the solution turned cloudy. The mixture was allowed to cool slowly to RT and then chilled at 0°C. The yellow solid precipitated was obtained by filtration. Further drying under vacuum overnight provide N-phenylsulfonyl-4-nitroaniline.
A cold (0°C) solution of N-phenylsulphonyl-4-nitroaniline (7.39 g, 30 mmol) in DMF (65 mL) was treated with sodium hydride (0.76 g, 32 mmol) portionwise over a period of 1.5 h. A solution of ethyl bromoacetate (4 mL) in DMF (10 mL) was added, and the resultant mixture stirred at RT overnight. The product mixture was concentrated under vacuum, and the residue dissolved in ethyl acetate. The organic extract was washed with brine, dried over magnesium sulfate, filtered and concentrated under vacuum. The residue was subjected to column chromatography on silica gel eluting with 0.5% methanol in chloroform. Collection and concentration of appropriate fractions provided N-4-nitrophenyl-N-phenylsulfonylglycine ethyl ester (4-8a) as a clear gum.
Figure imgf000055_0001
Step 2: N-{4-[4-(4-tert-Butyloxycarbonylpiperazin-1 - yl)phenylcarbonyl-amino]phenyl}-N-phenylsulfonylglycine ethyl ester (4-10a)
A solution of 4-8a (8.9 g, 24.4 mmol) in a mixture of ethanol (100 mL) and ethyl acetate (25 mL) was hydrogenated under an atmosphere of hydrogen gas at 45 psi in the presence of 5% Pd/C (0.89 g) at RT for 1.5 h. The resultant mixture was filtered through a plug of Celite, and the filtrate concentrated under vacuum. The residue was redissolved in toluene and concentrated under vacuum to provide the corresponding aniline.
A solution of 4-[4-(tert-butyloxycarbonyl)piperazin-1-yl]- benzoic acid (4-9 wherein R2 = H) (1.0 g, 3.3 mmol) in
dichloromethane (25 mL) and DMF (3 drops) at RT was treated with oxalyl chloride (0.43 mL, 4.9 mmol) over a period of 10 min. The resultant solution was stirred at RT for 1 h, and concentrated under vacuum. The residue was dissolved in toluene and concentrated to remove residual oxalyl chloride. The resultant acid chloride 4-9 was redissolved in dichloromethane (5 mL), and added to a cold (0°C) solution the above aniline (1.1 g, 3.3 mmol) and DMAP (0.48 g, 3.9 mmol) in dichloromethane (25 mL). The resultant mixture was stirred at RT overnight, diluted with dichloromethane and washed successively with 10% aq citric acid, sat. sodium bicarbonate, and brine. The organic extract was dried over magnesium sulfate, filtered and
concentrated under vacuum. The residue was subjected to column chromatography on silica gel eluting with 50% ethyl acetate in hexane. Collection and concentration of appropriate fractions provided 4-10a as a gum.
Figure imgf000056_0001
Step 3: N-{4-[4-(Piperazin-1-yl)phenylcarbonylamino]phenyl}-N- phenyl-sulfonylglvcine (4-11a) To a solution of the glycine ethyl ester 4-10a (260 mg, 0.41 mmol) in methanol (2.5 mL), aq. sodium hydroxide (0.85 mL, 1 M, 1.7 mmol) was added. The resultant mixture was stirred at RT for 2 h. The product mixture was concentrated, acidified, and extracted into dichloromethane. The combined organic extract were dried over sodium sulfate, filtered and concentrated under vacuum. The residue was dissolved in ethyl acetate (30 mL), cooled to 0°C, and treated with a steady stream of anhydrous hydrogen chloride gas for 10 min. The resultant solution was stirred at 0°C for 1 h, and concentrated under vacuum. The residue was dissolved in water, frozen and lyophilized overnight to provide glycine 4-11a as a white fluffy solid.
1H NMR (CD3OD): δ 7.89 (2H, d, J=8.8Hz), 7.69-7.50 (7H, m), 7.17 (2H, d, J=8.8Hz), 7.11 (2H, d, J=9.0Hz), 4.42 (2H, s), 3.6 (4H, m), 3.4
(4H, m).
Analysis calculated for C25H26N4O5S•0.15 EtOAc
C, 51.34; H, 5.00; N, 9.35
Found: C, 51.34; H, 4.96; N, 9.30
EXAMPLE 4B
Following the procedures described in Example 4A, Steps 1-3, but substituting the appropriate reagents as described below, the following compounds were made: (1) N-{4-[4-(Piperazin-1-yl)phenylcarbonylamino]phenyl}-N- thienylsulfonylglycine (4-11b)
This product was prepared using 2-thiophene sulfonyl chloride in place of phenylsulfonyl chloride in Step 1.
Analysis calculated for C25H26N4O5S• 1.40 TFA•0.15 H2O
C, 46.74; H, 3.91; N, 8.45
Found: C, 46.73; H, 3.92; N, 8.72
(2) N-{4-[4-(Piperazin-1-yl) phenylcarbonylaminolphenyl}-N-
2-fluoro-phenyl-sulfonylglycine (4-11c)
This product was prepared using 2-fluorophenyl-sulfonyl chloride in place of phenylsulfonyl chloride in Step 1. Analysis calculated for C25H25FN4O5S• 1.60 TFA
C, 48.74; H, 3.86; N, 8.06
Found: C, 48.37; H, 3.92; N, 8.46 (3) N-{4-[4-(Piperazin-1-yl)phenylcarbonylamino]phenyl}-N-
3-fluoro-phenylsulfonylglycine (4-11d)
This product was prepared using 3-fluorophenylsulfonyl chloride in place of phenylsulfonyl chloride in Step 1.
Analysis calculate for C25H25FN4O5S• 1.30 TFA• 0.35 H2O
C, 49.69; H, 4.08; N, 8.40
Found: C, 49.68; H, 4.04; N, 8.44
(4) N-{4-[4-(Piperazin-1-yl)phenylcarbonylaminolphenyl}-N- 4-fluorophenyl-sulfonylglycine (4-11e)
This product was prepared using 4-fluorophenylsulfonyI chloride in place of phenylsulfonyl chloride in Step 1..
Analysis calculated for C25H25FN4O5S• 1.35 TFA• 0.35 H2O
C, 49.45; H, 4.05; N, 8.33
Found: C, 49.45; H, 4.00; N, 8.40
(5) N-{4-[4-(Piperazin-1 -yl)phenylcarbonyla mino]-3- methylphenyl]-N-phenylsulfonylglycine (4-11f)
This product was prepared using 3-methyl-4-nitroaniline in place of 4-nitroaniline in Step 1.
Analysis calculated for C26H28N4O5S• 1.40 TFA• 0.42 H2O
C, 51.19; H, 4.51; N, 8.29
Found: C, 51.17; H, 4.51 ; N, 8.53
(6) N-{ 4-[4-(Piperazin-1 -yl)phenylcarbonylamino]-3-bromo- phenyl )-N-2-fluoro-phenvIsulfonylglycine (4-11 g)
This product was made using 3-bromo-4-nitroaniline and 2- fluorophenylsulfonyl chloride in place of 4-nitroaniline and
phenylsulfonyl chloride, respectively, in Step 1.
Analysis calculated for C25H24BrFN4O5S• 1.50 TFA• 0.35 H2O C, 43.75; H, 3.44; N, 7.29
Found: C, 43.76; H, 3.41; N, 7.53
(7) N-{4-[4-(Piperazin-1-yl)phenylcarbonylamino]phenyl }-N- trifluoro-methylsulfonylglycine (4-11h)
This product was prepared using trifluoromethanesulfonic anhydride and tert-butyl bromoacetate in place of phenylsulfonyl chloride and ethylbromo acetate, respectively, in Step 1.
Analysis calculated for C20H21F3N4O5S• 1.25 TFA• 0.35 H2O
C, 42.54; H, 3.64; N, 8.82
Found: C, 42.55; H, 3.60; N, 9.05
Figure imgf000059_0001
(8) N-{4-[4-(Piperazin-1 -yl)phenylcarbonylaminolphenyl}-N-
(1R)-10-camphorsulfonylsulfonylglycine (4-11i)
This product was prepared using (1R)-(-)-10- camphorsulfonyl chloride in place of phenylsulfonyl chloride in Step 1 Analysis calculated for C29H36N4O6S• 1.50 TFA• 0.15 H2O
C, 51.77; H, 5.13; N, 7.55
Found: C, 51.74; H, 5.13; N, 7.63
Figure imgf000060_0001
(9) N-{4-[4-(Piperazin-1-yl)phenyIcarbonylaminolphenyl }-N-
(1S)-10-camphorsulfonyl-sulfonyl-glycine (4-1 1 j)
This product was prepared using (1S)-(-)-10- camphorsulfonyl chloride in place of phenylsulfonyl chloride in Step 1..
Analysis calculated for C29H36N4O6S• 1.50 TFA• 0.10 H2O
C, 51.83; H, 5.12; N,7.56
Found: C, 51.84; H, 5.14; N, 7.72
Figure imgf000061_0001
SCHEME 5 CONTINUED wherein the precursors (5-13, 5-14 and 4-9) and the corresponding final products (5-15) have R1 , R2 and R3 defined as follows:
Figure imgf000062_0001
Figure imgf000063_0001
Step 1 : N-4-Nitrophenyl-N-benzoylglycine ethyl ester (5- 13a)
A mixture of 4-nitroaniline (4-7) (10.0 g, 72 mmol) and anhydrous potassium carbonate (20 g, 1.44 mmol) in anhydrous THF
(240 mL) and benzoyl chloride (9.1 mL, 78 mmol) was stirred at RT overnight. The resultant solution was poured into 10% aq. HCl (200 mL) and cooled to 0°C. The yellow solid precipitated was filtered, washed successively with water (200 mL) and hexane (200 mL).
Further drying under vacuum overnight provided the required 4-nitro- N-benzoylaniline.
A cold (0°C) solution of the above nitro aniline (4.8 g, 19.8 mmol) in DMF (40 mL) was treated portionwise with sodium hydride (0.48 g, 20 mmol). After the mixture was stirred at 0°C for 0.5 h, a solution of ethyl bromoacetate (2.6 mL, 23.4 mmol) in DMF (20 mL) was added. The resultant mixture was stirred at 50°C overnight and concentrated under vacuum. The residue was partitioned between ethyl acetate and water. The organic extract was washed with brine, dried over magnesium sulfate, filtered, and concentrated under vacuum to provide the nitrophenyl glycine ester 5-13a.
Figure imgf000064_0001
Step 2: N-{4-[4-(4-tert-Butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonyl-amino]phenyl }-N-benzoylglycine ethyl ester (5 -14a)
Following the procedure described for 4-10a, but substituting N-4-nitrophenyl-N-benzoyl-glycine ethyl ester (5-13a) for
N-4-nitrophenyl-N-phenylsulfonyl-glycine ethyl ester (4-8a), 5-14a was prepared.
Figure imgf000064_0002
Step 3: N-{4-[4-(Piperazin-1-yl)phenylcarbonylamino]phenyl }-N- benzoyl-glycine (5-15a)
Following the procedure described for 4-1 1 a, but substituting N-{4-[4-(4-tert -butyloxycarbonylpiperazin-1-yl)phenyl- carbonylaminojphenyl }-N-benzoylglycine ethyl ester (5-14a) for N-{4- [4-(4-tert -butyloxycarbonylpiperazin-1 -yl)phenylcarbonyl- amino]phenyl}-N-phenylsulfonylglycine ethyl ester (4- 10a), 5-15a was prepared.
Analysis calculated for C26H26N4O4• 1.35 TFA• 0.30 H2O
C, 55.79; H, 4.56; N, 9.07
Found: C, 55.76; H, 4.57; N, 9.29
Figure imgf000065_0001
Step 1 : N-4-Nitrophenyl-N-2-fluorobenzoyl-glycine ethyl ester (5- 13b)
Following the procedure described for 5-13 a, but substituting 2-fluorobenzoyl chloride for benzoyl chloride, 5-13b was prepared.
Figure imgf000065_0002
Step 2: N-{4-[4-(4-tert-Butyloxycarbonyl-piperazin-1-yl)- phenylcarbonyl-amino]phenyl }-N-2-fluorobenzoylglycine ethyl ester (5-14b)
Following the procedure described for 4-10a, but substituting N-4-nitrophenyl-N-2-fluorobenzoyl-glycine ethyl ester (5-
13b) for N-4-nitrophenyl-N-phenylsulfonylglycine ethyl ester (4-8a), 5-
14b was prepared.
Figure imgf000066_0001
Step 3: N-{4-[4-(Piperazin-1-yl)phenyIcarbonylaminolphenyl }-N-
2-fluoro-benzoylglycine (5- 15b)
Following the procedure described for 4-1 la, but substituting N-{4-[4-(4-tert-butyloxycarbonyl-piperazin-1-yl)- phenylcarbonylamino]phenyl }-N-2-fluorobenzoyl-glycine ethyl ester
(5-14b) for N-{ 4-[4-(4-rert-butyloxycarbonyl-piperazin-1-yl)- phenylcarbonylamino]phenyl}-N-phenylsuIfonylglycine ethyl ester
(4-10a), 5-15b was prepared.
Analysis calculated for C26H25FN4O4• 1.35 TFA• 0.15 H2O
C, 54.45; H, 4.24; N, 8.85
Found: C, 54.45; H, 4.26; N, 8.78
Figure imgf000067_0001
Step 1 : N-4-Nitrophenyl-N-3-fluorobenzoylglycine ethyl ester (5-13c)
Following the procedure described for 5-13a, but substituting 3-fluorobenzoyl chloride for benzoyl chloride, 5-13c was prepared.
Figure imgf000067_0002
Step 2: N-{4-[4-(4-tert-Butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonyl-amino]phenyl }-N-3-fluorobenzoylglycine ethyl ester (5-14c)
Following the procedure described for 4-10a, but substituting N-4-nitrophenyl-N-3-fluorobenzoyl-glycine ethyl ester
(5-13c ) for N-4-nitrophenyl-N-phenylsulfonylglycine ethyl ester (4-8a), 5- 14c was prepared.
Figure imgf000068_0001
Step 3: N-{4-[4-(piperazin-1-yl)phenylcarbonylamino]phenyl }-N-
3-fluoro-benzoylglycine (5-15c)
Following the procedure described for 4-1 1a, but substituting N-{4-14-(4-tert -butyloxycarbonyl-piperazin-1-yl)- phenyIcarbonylamino]phenyl }-N-3-fluorobenzoyl-glycine ethyl ester (5-14c) for N-{4-[4-(4-t ert-butyloxycarbonyl-piperazin-1-yl)- phenylcarbonylamino]phenyl}-N-phenylsulfonylglycine ethyl ester
(4-10a), 5-15c was prepared.
Analysis calculated for C26H25FN4O4• 1.70 TFA• 0.35 H2O
C, 52.19; H, 4.08; N, 8.28
Found: C, 52.19; H, 4.08; N, 8.42
Figure imgf000068_0002
Step 1 : N-4-Nitrophenyl-N-4-fluorobenzoylglvcine ethyl ester (5-13d) Following the procedure described for 5-13a, but
substituting 4-fluorobenzoyl chloride for benzoyl chloride, 5-13d was prepared.
Figure imgf000069_0001
Step 2: N- { 4-[ 4-(4-tert -Butyloxycarbonyl-piperazin-1-yl)- phenylcarbonyl-aminolphenyl}-N-4-fluorobenzoylglycine ethyl ester (5-14d)
Following the procedure described for 4-10a, but
substituting N-4-nitrophenyl-N-4-fluorobenzoylglycine ethyl ester
(5-13d) for N-4-nitrophenyl-N-phenylsulfonylglycine ethyl ester (4-8a ),
5-14d was prepared.
Figure imgf000069_0002
Step 3: N-{4-[4-(Piperazin-1 -yl)phenylcarbonylamino]phenyl }
N-4-fluoro-benzoylglycine (5-15d) Following the procedure described for 4-1 1a. but substituting N-{4-[4-(4-tert -butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonylamino]phenyl}-N-4-fluorobenzoyl-glycine ethyl ester (5-14d) for N-{ 4-[4-(4-tert -butyloxycarbonyl-piperazin- 1-yl)- phenylcarbonylamino]phenyl}-N-phenylsulfonylglycine ethyl ester (4-10a), 5-15d was prepared.
Analysis calculated for C26H25FN4O4• 1.40 TFA• 0.30 H2O
C, 53.92; H, 4.24; N, 8.73
Found: C, 53.90; H, 4.23; N, 8.83
Figure imgf000070_0001
Step 1 : N-4-Nitrophenyl-N-picolinoyl-glycine ethyl ester (5-13d)
Following the procedure described for 5-13a. but substituting picolinoyl chloride hydrochloride for benzoyl chloride, 5- 13d was prepared.
Figure imgf000070_0002
Step 2 N- { 4-[4-(4-tert-Butyloxycarbonyl-piperazin-1-yl)- phenylcarbonyl-amino]phenyl }-N-picolinoylglycine ethyl ester (5-14e)
Following the procedure described for 4-10a, but substituting N-4-nitrophenyl-N-picolinoyl-glycine ethyl ester (5-13d) for N-4-nitrophenyl-N-phenylsulfonylglycine ethyl ester (4-8a), 5-14e was prepared.
Figure imgf000071_0001
Step 3 N-{4-[4-(Piperazin-1 -yl)phenylcarbonylaminojphenyl }-
N-picolinoyl-glycine (5-15e)
Following the procedure described for 4-1 1a, but substituting N-{4-[4-(4-tert-butyloxycarbonyl-piperazin-1-yl)- phenylcarbonylamino]phenyl}-N-picolinoylglycine ethyl ester (5-14e) for N-{4-[4-(4-tert -butyloxycarbonyl-piperazin-1-yl)-phenylcarbonyI- aminojphenyl}-N-phenylsulfonylglycine ethyl ester
(4-10a), 5-15e was prepared.
Analysis calculated for C25H25N5O4• 2.10 TFA• 0.20 H2O
C, 49.92; H, 3.95; N, 9.97
Found: C, 49.88; H, 3.95; N, 10.04
Figure imgf000072_0001
Step 1 : N-4-Nitrophenyl-N-nicotinoyl-glycine ethyl ester (5-13f)
Following the procedure described for 5-13a, but substituting nicotinoyl chloride hydrochloride for benzoyl chloride, 5- 13f was prepared.
Figure imgf000072_0002
Step 2: N-{4-[4-(4-tert- Butyloxycarbonyl-piperazin-1-yl)- phenylcarbonyl aminojphenyl }-N-nicotinoylglycine ethyl ester (5-14f)
Following the procedure described for 4-10a, but
substituting N-4-nitrophenyl-N-picolinoyl-glycine ethyl ester (5-13f) for N-4-nitrophenyl-N-phenylsulfonylglycine ethyl ester (4-8a), 5-14f was prepared.
Figure imgf000073_0001
Step 3 N- { 4-[4-(Piperazin-1-yl)phenylcarbonylamino]phenyl}-N- nicotinoyl-glycine (5-15f)
Following the procedure described for 4-1 1a, but substituting N-{4-[4-(4-tert-butyloxycarbonyl-piperazin-1-yl)- phenylcarbonylamino]phenyl }-N-nicotinoylglycine ethyl ester (5-14f) for N-{4-[4-(4-tert -butyloxycarbonyl-piperazin-1 -yl)-phenylcarbonyl- amino]phenyl}-N-phenylsulfonylglycine ethyl ester (4-10a), 5-15f was prepared.
Analysis calculated for C25H25N5O4• 2.20 TFA• 0.35 H2O
C, 49.27; H, 3.92; N, 9.77
Found: C, 49.25; H, 3.92; N, 10.12
Figure imgf000073_0002
Step 1 : N-4-Nitrophenyl-N-isonicotinoyl-glycine ethyl ester (5- 13g) Following the procedure described for 5-13a, but substituting isonicotinoyl chloride hydrochloride for benzoyl chloride, 5-13g was prepared.
Figure imgf000074_0001
Step 2: N-(4-[4-(4-tert -Butyloxycarbonyl-piperazin-1-yl)- phenylcarbonyl-amino]phenyl}-N-isonicotinoylglycine ethyl ester (5-14 g)
Following the procedure described for 4-10a, but substituting N-4-nitrophenyl-N-isonicotinoyl-glycine ethyl ester (5-13g) for N-4-nitrophenyl-N-phenylsulfonylglycine ethyl ester (4-8a), 5-14g was prepared.
Figure imgf000074_0002
Step 3 : N-{4-[4-(Piperazin-1 -yl)phenylcarbonylaminolphenyl}-N- isonicotin-oyl-glycine (5-15g)
Following the procedure described for 4-1 1a, but substituting N-{4-[4-(4-tert -butyloxycarbonyl-piperazin-1 - yl)phenylcarbonylamino]phenyl}-N-isonicotinoylglycine ethyl ester (5-14g) for N-{4-[4-(4-tert-butyloxycarbonyl-piperazin-1-yl)- phenylcarbonylamino]phenyl}-N-phenyIsulfonylglycine ethyl ester (4-10a), 5-15g was prepared.
Analysis calculated for C25H25N5O4• 2.35 TFA• 0.65 H2O
C, 48.26; H, 3.91; N, 9.47
Found: C, 48.25; H, 3.90; N, 9.57
Figure imgf000075_0001
Step 1 : N-4-Nitrophenyl-N-acetyl-glycine ethyl ester (5-13h)
Following the procedure described for 5-13a , but substituting acetyl chloride for benzoyl chloride, 5-13h was prepared.
Figure imgf000075_0002
Step 2: N-{4-[4-(4-tert -Butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonyl-amino]phenyl}-N-acetylglycine ethyl ester
(5-14h)
Following the procedure described for 4-10a, but
substituting N-4-nitrophenyl-N-acetyl-glycine ethyl ester (5-13h) for N-
4-nitrophenyl-N-phenylsulfonylglycine ethyl ester (4-8a), 5-14h was prepared.
Figure imgf000076_0001
Step 3: N-{4-[4-(Piperazin-1-yl)phenylcarbonyl mino]phenyl }-N- acetyl-glycine (5-15h)
Following the procedure described for 4-1 1a, but substituting N-{4-[4-(4-tert-butyloxycarbonyl-piperazin-1-yl)- phenylcarbonylaminolphenyl }-N-acetylglycine ethyl ester (5-14h) for N-{4-[4-(4-tert-butyloxycarbonyl-piperazin-1-yl)-phenyIcarbonyl- aminojphenyl}-N-phenylsulfonylglycine ethyl ester (4-10a), 5-15h was prepared.
Analysis calculated for C21H24N4O4• 1.30 TFA• 0.55 H2O
C, 51.1 1 ; H, 4.80; N, 10.10
Found: C, 51.09; H, 4.74; N, 10.25
Figure imgf000077_0001
Step 1 : N-4-Nitrophenyl-N-cyclopropanecarboxylglycine ethyl ester (5-13i)
Following the procedure described for 5-13a, but substituting cyclopropanecarbonyl chloride for benzoyl chloride, 5-13i was prepared.
Figure imgf000077_0002
Step 2: N-{4-[4-(4-tert-Butyloxycarbonyl-piperazin-1 -yl)- phenyIcarbonyl-amino]phenyl}-N-cyclopropane- carboxylglycine ethyl ester (5-14i)
Following the procedure described for 4-10a, but substituting N-4-nitrophenyl-N-cyclopropanecarboxylglycine ethyl ester
(5-13i) for N-4-nitrophenyl-N-phenylsulfonylglycine ethyl ester (4-8a),
5-14i was prepared.
Figure imgf000078_0001
Step 3: N-{4-[4-(Piperazin-1-yl)phenylcarbonylamino]phenyl}-N- cyclopropanecarboxylglycine (5-15i)
Following the procedure described for 4-1 1a, but substituting N- { 4-[4-(4-tert -buty loxycarbonyl-piperazin-1 -yl)- phenylcarbonylaminolphenyl} -N-cyclopropanecarboxylglycine ethyl ester (5-14i) for N-{4-[4-(4-tert -butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonylaminolphenyl}-N-pheny Isulfonylglycine ethyl ester
(4-10a), 5-15i was prepared.
Analysis calculated for C23H26N4O4• 1.38 TFA• 0.62 H2O
C, 52.35; H, 4.88; N, 9.48
Found: C, 52.35; H, 4.86; N, 9.65
Figure imgf000078_0002
Step 1 : N-4-Nitrophenyl-N-benzyloxyacetyl-glycine ethyl ester (5-13j)
Following the procedure described for 5-13a, but substituting benzyloxyacetyl chloride for benzoyl chloride, 5-13j was prepared.
Figure imgf000079_0001
Step 2: N-{4-[4-(4-tert -Butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonyl-aminolphenyl} -N-benzyloxyacetylglycine ethyl ester (5-14j)
Following the procedure described for 4- 10a, but substituting N-4-nitrophenyl-N-benzyloxyacetylglycine ethyl ester
(5-13j) for N-4-nitrophenyl-N-phenylsulfonylglycine ethyl ester
(4-8a), 5-14j was prepared.
Figure imgf000079_0002
Step 3: N-{4-[4-(Piperazin-1-yl)phenyIcarbonylamino]phenyl}-N- benzyloxy-acetylglycine (5-15j)
Following the procedure described for 4-1 1a, but substituting N-{4-[4-(4-tert -butyloxycarbonyl-piperazin-1-yl)- phenylcarbonylamino]phenyl}-N-benzyloxy-acetylglycine ethyl ester (5-14j) for N-{4-[4-(4-tert-butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonylamino]phenyl }-N-phenylsulfonylglycine ethyl ester (4- 10a), 5-15j was prepared. Analysis calculated for C28H30N4O5• 1.56 TFA• 0.30 H2O
C, 54.50; H, 4.73; N, 8.17
found: C, 54.49; H, 4.73; N, 8.51
Figure imgf000080_0001
N-{4-[4-(Piperazin-1-yl)phenylcarbonylaminolphenyl }-N-hydroxy- acetylglycine (5-15k)
A mixture of N-{4-[4-(piperazin-1-yl)phenylcarbonyl- amino]phenyl}-N-benzyloxyacetylglycine (5-15 j, 100 mg), 5% Pd (10 mg) on charcoal, TFA (1 mL) and ethanol (10 mL) was stirred under a balloon of hydrogen gas for 18 h at RT. The resultant mixture was concentrated, and the residue subjected to column chromatography on a reverse phase C-18 column to provide 5-15k.
Analysis calculated for C21H24N4O5• 1.45 TFA• 0.40 H2O
C, 49.07; H, 4.52; N, 9.58
Found: C, 49.08; H, 4.47; N, 9.68
Figure imgf000081_0001
Step 1 : N-3-Methyl-4-nitrophenyl-N-benzoyl-glycine ethyl ester (5-131)
Following the procedure described for 5-13a, but substituting 3-methyl-4-nitroaniIine for 4-nitroaniline, 5-131 was
prepared.
Figure imgf000081_0002
Step 2: N-{4-[4-(4-tert-Butyloxycarbonyl-piperazin- 1 -yl)- phenylcarbonyl-aminol-3-methyl-phenyl }-N- benzoylglycine ethyl ester (5-141)
Following the procedure described for 4-10a, but substituting N-3-methyl-4-nitrophenyl-N-benzoyl-glycine ethyl ester (5-131) for N-4-nitrophenyl-N-phenylsulfonylglycine ethyl ester (4-8a), 5-141 was prepared.
Figure imgf000082_0001
Step 3: N-{4-[4-(Piperazin-1 -yl)phenylcarbonylamino]-3-methyl- phenyl}-N-2-benzoylglycine (5-151)
Following the procedure described for 4-11a, but substituting N-{4-[4-(4-tert-butyloxycarbonyl-piperazin- 1 -yl)- phenylcarbonylamino]-3-methyl-phenyl}-N-benzoylglycine ethyl ester
(5-141) for N-{4-[4-(4-tert-butyloxycarbonyl-piperazin-1-yl)- phenylcarbonylamino]phenyl }-N-phenylsulfonylglycine ethyl ester
(4-10a), 5-151 was prepared.
Analysis calculated for C27H28N4O4• 1.52 TFA• 0.54 H2O
C, 55.04; H, 4.70; N, 8.55
found: C, 55.03; H, 4.71; N, 8.84
Figure imgf000083_0001
Step 1 : N-2-Methyl-4-nitrophenyl-N-benzoyl-glycine ethyl ester (5-13m)
Following the procedure described for 5-13a, but substituting 2-methyl-4-nitroaniline for 4-nitroaniline, 5-13m was prepared.
Figure imgf000083_0002
Step 2: N-{4-[4-(4-tert-Butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonyl-amino]-2-methyl-phenyl }-N- benzoylglycine ethyl ester (5-14m)
Following the procedure described for 4-10a, but substituting N-2-methyl-4-nitrophenyl-N-benzoylglycine ethyl ester (5-13m) for N-4-nitrophenyl-N-phenylsulfonylglycine ethyl ester (4-8a,. 5-14m was prepared.
Figure imgf000084_0001
Step 3: N-{ 4-[4-(Piperazin-1-yl)phenyIcarbonyla mino]-2-memy phenyl } -N-2-benzoylglycine (5- 15m)
Following the procedure described for 4-11a, but substituting N-{4-[4-(4-tert-buty loxycarbonyl-piperazin-1 -y1)- pheny Icarbony lamino]-2-methyl-phenyl} -N-benzoylglycine ethyl ester
(5-14m) for N-{4-[4-(4-ter t-butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonylaminojphenyl }-N-phenyIsulfonylglycine ethyl ester 4-10a), 5-15m was prepared.
Analysis calculated for C27H28N4O4• 1.56 TFA• 0.58 H2O
C, 54.74; H, 4.69; N, 8.48
Found: C, 54.75; H, 4.69; N, 8.74
Figure imgf000085_0001
Step 1 : N-{4-[4-(4-tert-Butyloxycarbonyl-piperazin-1-yl)-3- methylphenyl-carbonylaminol-phenyl}-N-benzoylglycine ethyl ester (5-14n)
Following the procedure described for 4-10a, but substituting N-4-nitrophenyl-N-benzoylglycine ethyl ester (5- 13a) for N-4-nitrophenyl-N-phenylsulfonylglycine ethyl ester (4-8a), and substituting 4-[4-(tertbutyloxycarbonyl)piperazin-1 -yl]-3- methylbenzoic acid for 4-[4-(tert -butyloxycarbonyl)piperazin- 1 -yl]- benzoic acid, 5-14n was prepared.
Figure imgf000085_0002
Step 2: N-{4-[4-(Piperazin-1-yl)-3-methyl-phenylcarbonylaminol- phenyl )-N-benzoylglycine (5-15n)
Following the procedure described for 4-11a, but substituting N-{4-[4-(4-tert -butyloxycarbonyl-piperazin-1-yl)-3- methyIpheny Icarbony lamino] -phenyl}-N-benzoylglycine ethyl ester (5-14n) for N-{4-[4-(4-tert -butyloxycarbonyl-piperazin-1-yl)- phenylcarbonylamino]phenyl}-N-pheny Isulfonylglycine ethyl ester (4-10a), 5-15n was prepared.
Analysis calculated for C27H28N4O4• 1.42 TFA• 0.44 H2O
C, 55.79; H, 4.75; N, 8.72
Found: C, 55.80; H, 4.76; N, 8.78
Figure imgf000086_0001
Step 1: N-{4-[4-(4-tert -Butyloxycarbonyl-piperazin-1-yl)-2- methylphenyl-carbonylamino]-phenyl}-N-benzoylglycine ethyl ester (5-14o)
Following the procedure described for 4-10a, but substituting N-4-nitrophenyl-N-benzoylglycine ethyl ester (5-13a) for N-4-nitrophenyl-N-phenyIsulfonylglycine ethyl ester (4-8a), and substituting 4-[4-(tert-butyloxycarbonyl)piperazin-1-yl]-2-methyl- benzoic acid for 4-[4-(tert -butyloxycarbonyl)piperazin-1-yl]-benzoic acid, 5-14o was prepared.
Figure imgf000087_0001
Step 2: N-{4-[4-(Piperazin-1 -yl)-2-methylphenylcarbonylamino]- phenyl }-N-benzoylglycine (5-15o)
Following the procedure described for 4-11a, but substituting N-{4-[4-(4-tert -butyloxycarbonyl-piperazin-1 -yl)-2- methylphenylcarbonylamino]-phenyl }-N-benzoylglycine ethyl ester (5-14o) for N-{4-[4-(4-tert- butyloxycarbonyl-piperazin-1-yl)- phenylcarbonylaminojpheny1 }-N-pheny Isulfonylglycine ethyl ester (4-10a), 5-15o was prepared.
Analysis calculated for C27H28N4O4• 1.56 TFA• 0.46 H2O
C, 54.92; H, 4.66; N, 8.51
Found: C, 54.93; H, 4.67; N, 8.58
Figure imgf000088_0001
Figure imgf000089_0001
Step 1 : 9-H-2-(1 ,1-Dimethylethoxycarbonyl)-7-bromo β-carboline
(6-2 )
A suspension of 6-1, prepared by the method of Rinehart et ai, (JACS, 1987, 109, p 3378-3387) (0.366 g, 1.46 mmol) in CH2CI2 (8 mL) was treated with triethylamine (0.61 mL, 4.4 mmol) followed by di-tert-butyldicarbonate (0.38 g, 1.7 mmol) for 1 hour at room temperature. The solution was concentrated and the residue
chromato graphed (20% EtOAc/Hexanes) to give 6-2 as a white solid.
Rf(20% EtOAc/Hexanes) 0.28
1H NMR (400 MHz, CDCI3) δ 8.0-7.6 (m, 1H), 7.46 (s, 1H), 7.33 (d, 1H), 7.2 (d, 1H), 4.6 (bs, 2H), 3.78 (bs, 2H), 2.76 (bs, 2H), 1.5 (s, 9H).
Step 2: 9-H-2-(1 ,1-Dimethylethoxycarbonyl)-β-carbolin-7-yl
carboxylic acid (6-3)
A solution of 6-2 (0.26 g, 0.734 mmol) in THF (10 mL) was cooled to 0°C and treated with methylmagnesium chloride (3.0 M in THF, 0.29 mL, 0.87 mmol) to give a pale yellow solution. After 15 minutes the solution was cooled to -78°C and treated with t-BuLi (1.7M in pentane, 4.35 mL, 7.39 mmol) to give a bright yellow solution.
After 10 minutes CO2 gas was bubbled vigorously through the solution for 10 minutes. Saturated NH4CI, water and enough 6N NaOH to reach pH12 were added and the solution extracted with EtOAc. The EtOAc layer was back extracted with 0.5 NaOH and the aqueous layers combined, acidfied to pH 7 and extracted with EtOAc, the EtOAc layer was dried (Na2SO4) filtered and concentrated to give 6- 3 as an off- white solid.
Rf(75:25:1 CHCl3/MeOH/HOAc)0.48.
1H NMR (400 MHz, DMSO-d6) δ 12.0 (bs, 1H), 1 1.2 (s, 1H), 7.93 (s, 1H), 7.6 (d, 1H), 7.45 (d, 1H), 4.6 (s, 2H), 3.68 (m, 2H), 2.7 (m, 2H), 1.4 (s, 9H).
Step 3: N-{4-[9-Boc-β-carbolme-7-yl)carbonylamino]phenyl } -N- phenyl-sulfonyl glycine (6-4)
A solution of 6-3 (0.075 g, 0.24 mmol) and N-4- aminophenyl-N-phenylsulfonylglycine ethyl ester (0.086 g, 0.28 mmol) in CH2CI2 (3 mL) was treated with diisopropylamine and PYCLU to give 6- 4 as a white solid after chromatography in a gradient of 40 to
50% EtOAc/Hexanes.
Rf(40% EtOAc/Hexanes)0.13
1H NMR (400 MHz, CDCI3) δ 8.5-8.2 (m, I H), 8.0 (d, 1H), 7.2 (2s,
2H), 7.6 (2s, 2H), 7.58 (m, 1H), 7.53 (s, 2H), 7.47 (m, 2H), 7.2 (d, 2H),
4.68 (bs, 2H), 4.4 (s, 2H), 4.13 (q, 2H), 3.8 (bs, 2H), 2.7 (bs, 2H), 1.5
(s, 9H), 1.2 (t, 3H). Step: 4 N-{4-[(9-H-β-Carboline-7-yl)carbonylamino]phenyl }-N- phenyl-sulfonyl glycine (6-5)
A solution of 6-4 (0.088 g, 0.139 mmol) in EtOAc (15 mL) was treated first with HCl gas, then with LiOH•H2O to give 6-5 as a white solid after chromatography in 18:1 : 1 E.OH/H2O/NH4OH.
Rf(18:1 : 1 EtOH/H2O/NH4OH) 0.43
1H NMR (400 MHz, D2O) δ 7.79 (s, 1H), 7.6 (m, 1H), 7.52 (m, 2H), 7.46 (m, 4H), 7.32 (d, 2H), 7.08 (d, 2H), 4.08 (s, 2H), 3.84 (s, 2H), 2.95 (m, 2H), 2.63 (m, 2H).
Figure imgf000091_0001
Figure imgf000092_0001
EXAMPLE 7
Step 1 : 4-(4-Pyridyl)phenylcarboxylate (7-2)
A slurry of 7-1 (5g, 29.6 mmol, prepared as described in
Chambron, J.C.; Sauvage, J.P., Tetrahedron, 1987, 895 and Comins, D.L.; Abdullah, A.H., J. Org. Chem., 1982, 47, 4315 method B) in 200 mL H2O was treated with 10% HCl until the solids dissolved. The solution was treated with solid KMnO4 in portions (11.2 g, 888 mmol), stirred until the KMnO4 had dissolved and heated to 90°C for 18 hr. An additional 2 g of KMnO4 was added and the reaction was again heated to 90°C for 2 hr. The reaction was cooled to ~60°C, filtered and the solids were washed with warm water. The filtrate was evaporated and the residue chromatographed (Silica gel, 10:1 :1 EtOH/H2O/NH4OH) to give 7- 2 as an off -white solid.
1H NMR (400 MHz, DMSO) δ 8.61 (m, 2H), 8.0 (m, 2H), 7.72 (m, 4H). Step 2: 4-(4-N-BOC-piperidinyl)phenylcarboxylate (7-3)
A solution of 7-2 (0.5 g, 2.5 mmol) in 20 mL 20%
HOAc/MeOH was treated with 250 mg PtO2 and hydrogenated at 50 psi for 4 hr. The solution was filtered through Solka Floe, evaporated and azeotroped with heptane to remove excess HOAc. The intermediate amino acid acetic acid salt was obtained as a white solid.
Rf(10:1 :1 EtOH/H2O/NH4OH) 0.3.
1H NMR (400 MHz, CD3OD) δ 8.96 (m, 2H), 7.35 (m, 2H), 3.5 (bd, 2H), 3.4 (m, 2H), 3.2 (m, 2H), 3.0 (m, 2H).
A slurry of the amino acid (0.5 g, 1.9 mmol) in 30%
H2O/dioxane (12 mL) was treated with 1 N NaOH (4.8 mL) and di-tert- butyldicarbonate (0.564 g, 2.58 mmol) at room temperature for 6 hr. The reaction was acidified to pH 5 with 10% KHSO4 and extracted several times with EtOAc.
The EtOAc layers were combined and evaporated to give 7-
3. as a white solid.
Rf(97:3:1 CHCl3/MeOH/HOAc) 0.39.
1H NMR (400 MHz, CD3OD) δ 7.95 (d, 2H), 7.33 (d, 2H), 4.2 (bd, 2H), 2.85 (b, 3H), 1.8 (bd, 2H), 1.6 (m, 2H), 1.48 (s, 9H).
Step 3: Ethyl 2-(1 -phenylsulfonamido-4-(4-(N-(1,1- dimethylethoxycarbonyl)-piperidin-4-yl)phenyl- carboxamide)-phenyl)acetate (7-4)
A solution of 7-3 (0.457 g, 1.5 mmol) N-4-aminophenyl-N- phenyl sulfonylglycine ethyl ester (0.50 g, 1.5 mmol) in CH2CI2 (10 mL) was treated with diisopropylamine (0.287 mL, 1.65 mmol) and PYCLU (0.594 g, 1.65 mmol) and stirred at room temperature for 24 hours. The solution was diluted with EtOAc and washed with H2O, 10% citric acid, saturated NaHCO3 and brine, dried over MgSO4, filtered and evaporated to give 7-4 as a tan oil. Rf(50%
EtOAc/Hexanes)0.16
1 H NMR (400 MHz, CDCI3) δ 7.8 (d, 1H), 7.7 (d, 1H), 7.58 (m, 3H), 7.45 (m, 2H), 7.32 (d, 1H), 7.2 (d, 1H), 4.4 (s, 2H), 4.25 (m, 2H), 4.15 (q, 2H), 2.82 (m, 2H), 2.78 (m, 1H), 1.82 (bd, 2H), 1.6 (m, 3H), 1.45 (s, 9H), 1.2 (t, 3H).
Step 4: N- { 4-[4-N-Boc-piperidin-4-yl)phenylcarboxylamino]- phenyl} -N-phenylsulfonylglycine (7-5)
A solution of 7-4 (0.7 g, 1.12 mmol) in 1 : 1 : 1
MeOH/H2O/THF was treated with LiOH•H2O (0.097 g, 1.12 mmol) for
24 hours. The solution was diluted with EtOAc and 10% KHSO4 and the layers separated. The organic layer was dried over MgSO4, filtered and evaporated to give 7-5 as a tan solid.
Rf(9:1 :1 CH2Cl2/MeOH/HOAc)0.55
1H NMR (400 MHz, CD3OD) δ 7.89 (m, 2H), 7.65 (m, 5H), 7.05 (m,
2H), 7.8 (d, 2H), 7.18 (d, 2H), 4.4 (s, 2H), 4.2 (bd, 2H), 2.85 (m, 3H),
2.83 (bd, 2H), 1.6 (m, 1H), 1.48 (s, 9H).
Step 5: N-{4-[4-Piperidm-4-yl)phenylcarbonylamino]phenyl }-N- phenyl-sulfonylglycine (7-6)
A solution of 7-5 (0.4 g, 0.67 mmol) in EtOAc (5 mL) was cooled to -78°C, saturated with HCl gas, warmed to 0°C and stirred for 1 hour, then concentrated at ambient temperature to give 7-6 as a white solid after chromatography in 10:1 :1 EtOH/H2O/NH4OH.
Rf ( 10: 1 : 1 EtOH/H2O/NH4OH)0.34
1H NMR (400 MHz, D2O + NaOD) δ 7.65-7.4 (m, 7H), 7.35 (d, 2H),
7.26 (m, 2H), 7.05 (m, 2H), 4.08 (bs, 2H), 2.95 (m, 2H), 2.55 (m, 3H), 1.65 (m, 2H), 1.45 (m, 2H).
Figure imgf000095_0001
EXAMPLE 8
Step 1 : 4-(Pyridyl)piperidin-4-yl-carboxylic acid (8-1 )
Ethyl isonipecotate (6.0 g, 38.66 mmol), 4-chloropyridine hydrochloride (5.9 g, 38.66 mmol) and N-methylmorpholine (9.3 mL, 85.0 mmol) were dissolved in N-methylpyrrolidinone (50 mL) and the resulting solution heated at 100° for 48 h. The solution was
concentrated in vacuo and the residue dissolved in ethyl acetate (200 mL) and washed with water and brine (2 x 100 mL), then dried
(Na2SO4) and evaporated. The resulting residue was purified by flash chromatography (5%MeOH/CH2Cl 2) to afford ethyl 4- (pyridyl)piperidin-4-yl-carboxylate as a crystalline solid.
A solution of the above ester (10 g, 42.7 mmol) in THF (50 mL) was treated with 1N LiOH (47 mL, 47.0 mmol) and H2O (50 mL). The resulting solution was concentrated and the aqueous residue cooled to 0°C, then adjusted to pH = 6 with 1N HCl and the resulting solid 8-1, collected by filtration.
Step 2: N-{4-[N-(4-Pyridyl)-piperidinyl-4-carbonylamino}phenyl}- N-phenyl-sulfonyl-glycine methyl ester (8-2)
Following the procedure described for 4-10a. but
substituting N-(4-pyridyl)-piperidinyl-4-carboxylic acid (8-1) for 4-[4- (tert-butyloxycarbonyl)-piperazin-1-yl]benzoic acid, 8=2 was prepared. Step 3: N-{4-[N-(4-Pyridyl)-piperidinyl-4-carbonylamιuιo]phenyl}-
N-phenylsulfonyl-glycine (8-3)
Following the procedure described for 4-1 1a, N-{4-[N-(4- pyridyl)-piperidinyl-4-carbonylamino]phenyl }-N-ph enyIsulfonylglycine methyl ester 8-2 was hydrolyzed. HPLC purificati n provided 8-3. Analysis calculated for C25H25N4O5S• 1.40 TFA• 0.80 H2O
C, 50.02; H, 4.23; N, 8.39
Found: C, 50.00; H, 4.24; N, 8.65
Figure imgf000097_0001
EXAMPLE 9
Step 1 : N-4-(4-tert-Butyloxycarbonylpiperaziny-1-y)-benzoyl]-5- nitro-indoline (9-2)
Following the procedure described for 4-10a. but substituting 5-nitroindoline (9-1 ) for N-4-aminophenyl-N- phenylsulfonylglycine ethyl ester, 9-2 was prepared. Step 2: N-[4-(1 -tert-Butyloxycarbonylpiperaziny-1 -y)benzoyl]-5- phenyl-sulfonylamino-indoline (9-3)
Following the procedure described for 3-5a, but subtituting N-[4-(4-tert -butyloxycarbonylpiperaziny-1 -y)-benzoyl]-5-nitro-indoline (9-2) for nitrobenzene 3-4, 9-3 was prepared. The catalytic
hydrogenation was carried out in the presence of Pt/C in THF.
Step 3: N-{N-[4-(4-tert-Butyloxycarbonylpiperaziny-1-yl)- benzoyn-5-indolinyl}-N-phenylsufonyl-glycine (9-4)
Following the procedure described for 3-6a, but
substituting N-[4-(4-tert-butyloxycarbonylpiperaziny-1-y)-benzoyl]-5- phenylsulfonylamino-indoline (9-3) for sulfonamide 3-5a, 9-4 was prepared.
Analysis calculated for C27H28N4O5S• 1.50 TFA
C, 52.10; H, 4.30; N, 8.10
Found: C, 52.13; H, 4.26; N, 8.23
Figure imgf000099_0001
EXAMPLE 10
Step 1 : 5-Nitro-thiophene-2-carboxylic acid (10-2)
To a cold (0°C) mixture of 5-nitro-thiophene-2- carboxaldehyde (10-1) (7.86 g, 50 mmol), NaH2PO4 (1.86 g, dissolved in 20 mL water), 30% H2O2 (6 mL) in acetonitrile (50 mL), a solution of NaClO2 (8 g) in water (70 mL) was added over a period of 1 h. After stirring at RT for 5 h, the reaction mixture was treated with sodium sulfite (500 mg) and 1 M aq. HCl. The resultant mixture was extracted with ethyl acetate (3X). The organic extracts were combined, washed with brine, dried over anhdrous magnesium sulfate, filtered, and concentrated under vacuum to provide acid 10-2. Step 2: N-(5-Nitro-thiophene-2-carboxyl)-4-(4-tert - butyloxycarbonyl-piperaziny-1-yl)-aniline (10-3)
Following the procedure described for 3-4, but substituting 5-nitro-thiophene-2-carboxylic acid (10-2) for 4-nitrobenzoic acid, 10-3 was prepared.
Step 3: N-{2-[4-(4-tert-Butyloxycarbonylpiperazin-yl)- phenylamino-carbonyl]thien-5-yl }-N-phenylsulfonyl- glvcine methyl ester (10-4)
Following the procedure described for 3-5a. but substituting N-(5-nitro-thiophene-2-carboxyl)-4-(4-tert -butyloxy- carbonylpiperaziny-1 -yl)-aniline (10-3) for 3-4. The reduction was carried out in methanol in the presence of Pt2S for three hour under a balloon of hydrogen gas. Phenylsulfonylation, was described for 3-5a provided 10-4. Step 4: N-{2-[4-(1 -Piperazin-yl)-phenylaminocarbonyl]thien-5-yl }
N-phenyl-sulfonyl-glycine (10-5)
Following the procedure described for 3-6a, but substituting 10-4 for 3-5a, 10-5 was prepared.
Analysis calculated for C23H24N4O5S2• 1.72 TFA• 0.28 H2O
C, 45.25; H, 3.77; N, 7.98
found: C, 45.25; H, 3.77; N, 8.13
Figure imgf000102_0001
EXAMPLE 11
Step 1 : 6-Nitro-3,4-dihydroquinolin-2-(1H)-one (1 1 -2)
To a solution of 3,4-dihydroquinolin-2-(1H)-one (1.50 g) in
78% sulfuric acid (300 mL) at RT, a mixture of 69% nitric acid (0.84 mL) in 78% sulfuric acid (60 mL) was added. The reacting mixture was stirred at RT for 15 min, poured into ice-water, and extracted with methylene chloride (3 x 200 mL). The organic extracts were combined, washed with brine (4 x), dried over anhydrous magnesium sulfate, filtered and concentrated onto silica gel. The residue was loaded onto a column of silica gel, and eluted with 3% methanol in chloroform.
Collection and concentration of appropriate fractions provided the nitroquinolinone 1 1-2.
Step 2: 6-Nitro-1-carbomethox vmethyl-3,4-dihydroquinolin-2-(1H)-one
(1 1-3)
Following the procedure described for 5-13a, but
substituting 6-nitro-3,4-dihydroquinolin-2-(1H)-one (1 1-2) for 4-nitro- N-benzoylaniline, 1 1-3 was prepared.
Step 3: 6-[4-(4-tert-Butyloxycarbonyl-piperazin-1 -yl)- phenylcarbonylaminol-1-carbomethoxymethyI-3,4- dihydroquinolin-2-(1H)-one (11 -4)
Following the procedure described for 4-10a, but substituting 6-nitro-1-carbomethoxymethyl-3,4-dihydroquinolin-2-(1H)- one (1 1-3) for N-4-nitrophenyl-N-phenylsulfonyl-glycine ethyl ester (4-
8a), 1 1 -4 was prepared. Step 4: 6-[4-(4-Piperazin-1-yl)-phenylcarbonylamino]-1 - carbohydroxymethyl-3.4-dihvdroquinolin-2-(l H)-one (1 1 -5) Following the procedure described for 4-11 a, but substituting 6-[4-(4-tert -butyloxycarbonyl-piperazin-1 -yl)- pheny Icarbony lamino]- 1 -carbomethoxy-methyl-3 , 4-dihydroquinolin-2- (1H)-one (1 1-4) for 4- 10a, 1 1-5 was prepared.
Analysis calculated for C22H24N4O4• 1.22 TFA• 0.84 H2O
C, 52.17; H, 4.82; N, 9.96
Found: C, 52.15; H, 4.82; N, 10.13
EXAMPLE 12
Tablet Preparation Tablets containing 25.0, 50.0, and 100.0 mg., respectively, of the active compound p) from Table I are prepared as illustrated below:
TABLE FOR DOSES CONTAINING FROM 25-100MG OF THE ACTIVE COMPOUND
Figure imgf000104_0001
All of the active compound, cellulose, and a portion of the com starch are mixed and granulated to 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 25.0, 50.0, and 100.0 mg, respectively, of active ingredient per tablet. EX AMPLE 13
Intravenous formulations An intravenous dosage form of the above-indicated active compound is prepared as follows:
Active Compound 0.5-10.0mg
Sodium Citrate 5-50mg
Citric Acid 1 -15mg
Sodium Chloride 1 -8mg
Water for Injection (USP) q.s. to 1 L
Utilizing the above quantities, the active compound is dissolved at room temperature in a previously prepared solution of sodium chloride, citric acid, and sodium citrate in Water for Injection (USP, see page 1636 of United States Pharmacopeia/National Formulary for 1995, published by United States Pharmacopeial Convention, Inc., Rockville, Maryland, copyright 1994.
Therapeutic Treatment
Compounds of the invention may be administered to patients where inhibition of human or mammalian platelet aggregation or adhesion is desired.
Compounds of the invention are useful in inhibiting platelet aggregation and thus, they may find utility in surgery on peripheral arteries (arterial grafts, carotid endaterectomy) and in cardiovascular surgery where manipulation of arteries and organs, and/or the interation of platelets with artificial surfaces, leads to platelet aggregation and consumption. The aggregated platelets may form thrombi and
thromboemboli. Compounds of the invention may be administered to these surgical patients to prevent the formation of thrombi and
thromboemboli.

Claims

WHAT IS CLAIMED IS:
1. A compound of formula I
X-A-Y-Z-B I and the pharmaceutically acceptable salts, esters, solvates and
stereoisomers thereof wherein:
X is heterocycle;
heterocycle is selected from:
(1 ) a five or six membered saturated, partially unsaturated or aromatic ring which consists of carbon atoms and one, two or three heteroatoms selected from the group -O-, -N-, -N(R1)- and -S-, wherein one of the carbon atoms may be substituted with a member selected from R1 a and -NHR1, (2) an eight to ten membered bicyclic ring system which is saturated, or completely or partially unsaturated, and which consists of carbon atoms and one, two or three heteroatoms selected from the group -O-, -N-, -N(R1 )- and -S- , wherein one of the carbon atoms may be substituted with a member selected from R1 a and -NHR1 ,
(3) a thirteen to fourteen membered tricyclic ring system
which is saturated, or completely or partially unsaturated, and which consists of carbon atoms and one, two or three heteroatoms selected from the group -O-, -N-, -N(R1 )- and -S- , wherein one of the carbon atoms may be substituted with a member selected from R1 a and -NHR1 ;
A is a bond between X and Y or is selected from:
( 1 ) phenyl substituted with R1a,
(2) -N(R 1)-, and
Figure imgf000106_0001
Y is selected from:
(1) -C1 -8 alkyl-,
(2) -C4- 10 cycloalkyl-,
(3) -C0-8 alkyl-NR1-CO-C0-8 alkyl-,
(4) -C0-8 alkyl-CONR1-C0-8 alkyl-,
(5) -C0-8 alkyl-O-C0-8 alkyl-,
(6) -C0-8 alkyl-SOp-C0-8 alkyl-,
(7) -(CH2)0-8-aryl-(CH2)0-8-,
(8) (-CH2)0-6-aryl-SOp-
(9) -(CH2)0-8-aryl-CO-(CH2)0-8-,
(10) -(CH2)0-6-aryl-SOp-(CH2)0-6-,
(11 ) -(CH2)0-6-NR1-(CH2)0-6-,
(12) -(CH2)0-6-aryl-CH(OH)-(CH2)0-6
(13) -(CH2)0-8-aryl-CONH-(CH2)0-8-,
(14) -C0-8 alkyl-SOp-NR1-C0-8 alkyl-,
(15) -C0-8 alkyl-CO-C0-8 alkyl-, and
(16) -C0-8 alkyl-CH(OH)-C0-8-alkyl-; p is an integer selected from 0, 1 and 2;
Z is selected from aryl and heterocycle; aryl is a 5- or 6-membered aromatic ring system which is unsubstituted or mono-, di- or tri-substituted with R2;
B is
Figure imgf000107_0001
wherein m is an integer selected from 0 and 1 ; R1 and R3 are independently selected at each occurrence from:
(1 ) hydrogen,
(2) C1 - 10 alkyl-, (3) C3-8 cycloalkyl-,
(4) aryl-C0-8 alkyl-,
(5) amino-C0-8 alkyl-,
(6) C1-6 alkylamino-C0-8 alkyl-,
(7) C1-6 dialkylamino-C0-8 alkyl-,
(8) C1-3 acylamino-C0-8 alkyl-,
(9) C 1-4 alkoxy-C1-6 alkyl-,
(10) -C1-6 alkyl-CO2H,
(11) -C1-6 alkyl-CO2C1-3 alkyl,
(12) -O-C1-6 alkyl-CO2H and
(13) hydroxy-C1-6 alkyl-;
R1a is independently selected at each occurrence from:
(1) hydrogen,
(2) halogen,
(3) C1-10 alkyl-,
(4) C3-8 cycloalkyl-,
(5) aryl-C0-8 alkyl-,
(6) amino-C0-8 alkyl-,
(7) C1-6 alkylamino-C0-8 alkyl-,
(8) C1-6 dialkylamino-C0-8 alkyl-,
(9) C1-3 acylamino-C0-8 alkyl-,
(10) C1-4 alkoxy-C1-6 alkyl-,
(11) -C0-6 alkyl-CO2H,
(12) -C1-6 alkyl-CO2C1-3 alkyl,
(13) -O-C1-6 alkyl-CO2H,
(14) hydroxy C1-6 alkyl and
(15) oxo (=0); R2 is independently selected at each occurrence from:
(1) hydrogen,
(2) halogen,
(3) C1-10 alkyl-,
(4) C3-8 cycloalkyl-, (5) aryl-C0-8 alkyl-,
(6) amino-C0-8 alkyl-,
(7) C1-6 alkylamino-C0-8 alkyl-,
(8) C1 -6 dialkylamino-C0-8 alkyl-,
(9) C1-3 acylamino-C0-8 alkyl-,
(10) C1-4alkoxy-C1-6 alkyl-,
(11) -C1-6 alkyl-CO2H,
(12) -C1-6 alkyl-CO2C1-3 alkyl,
(13) -O-C1-6 alkyl-CO2H, and
(14) hydroxy C1-6 alkyl;
R4 is selected from
(1) -(CH2)p-D-R6 wherein p is defined above,
Figure imgf000109_0001
(4) when Z is unsubstituted or substituted phenyl and m is zero, R4 together with the nitrogen to which it is attached can form a bicyclic structure with Z (phenyl) as follows:
Figure imgf000109_0002
D is selected from -SO2- and -C(O)- R5 is selected from:
(1 ) -OH,
(2) C1 -8 alkyloxy-,
(3) aryl C0 -6 alkyloxy-,
(4) C1 -8 alkylcarbonyloxy C1 -4 alkyloxy-,
(5) aryl C1 -8 alkylcarbonyloxy C1 -4 alkyloxy-, and
(6) L- or D-amino acid joined by an amide linkage and wherein the carboxylic acid moiety of said amino acid is as the free acid or is esterified by C1 -6 alkyl; and R6 is selected from:
(1) - C1 -6alkyl, unsusbstituted, mono- or di-substituted with R1 a,
(2) -(C0 -6alkyl)aryl, wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(3) -(C0 -6alkyl)heterocycle, wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1 a,
(4) -NRl (C1 -6alkyl), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(5) -NR1 (C0 -6alkylaryl), wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1 a,
(6) -NR1(C0 -6alkylheterocycle), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(7) -C3-6 cycloalkyl, and
(8) -CF3.
2. The compound of claim 1 having the formula II
Figure imgf000110_0001
and the pharmaceutically acceptable salts, solvates and stereoisomers thereof wherein: X-A- together represent a group selected from:
Figure imgf000111_0001
n is an integer selected from 2, 3, 4, and 5; Q is selected from -N(R1)-, -S- and -O-;
Y is selected from:
(1) -C0-8 alkyl-NR1-CO-C0-8 alkyl-,
(2) -C0-8 alkyl-CONR1-C0-8 alkyl-,
(3) -C0-8 alkyl-O-C0-8 alkyl-,
(4) -C0-8 alkyl-SOp-C0-8 alkyl-,
(5) -(CH2)0-6-NR1-(CH2)0-6-,
(6) -C0-8 alkyl-SOp-NR1 -C0-8 alkyl-,
(7) -C0-8 alkyl-CO-C0-8 alkyl-, and
(8) -C0-8 alkyl-CH(OH)-C0-8-alkyl-; p is an integer selected from 0, 1 and 2;
Z is selected from
( 1 ) aryl and (2) a five or six membered saturated, partially unsaturated or aromatic heterocyclic ring which is unsubstituted, or
monosubstituted or disubstituted with R1 a, which consists of carbon atoms and one, two or three heteroatoms selected from the group -O-, -N-, -N(R 1 )- and -S-, and which may be fused to a benzene ring to form a bicyclic structure, for example,
Figure imgf000112_0001
aryl is a 5- or 6-membered aromatic carbon ring which is unsubstituted or mono-, di- or tri -substituted with R2;
R1 is independently selected at each occurrence from -H, C1 -10 alkyl,
C3-8 cycloalkyl-, aryl-C0-8 alkyl- and hydroxy-C0 -6 alkyl-;
R1 a is independently selected at each occurrence from -H, halogen, -C1 -10 alkyl, C3-8 cycloalkyl-, aryl-C0-8 alkyl-, and
amino-C0-8 alkyl-;
R2 is independently selected at each occurrence from -H, halogen,
-C1 -10 alkyl, C3-8 cycloalkyl-, aryl-C0-8 alkyl- and
C1 -4 alkoxy-C0-8 alkyl-;
R3 is independently selected at each occurrence from -H, -C1 -10 alkyl, C3-8 cycloalkyl- and aryl-C0-8 alkyl-;
R5 is selected from:
(1 ) -OH,
(2) C1 -8 alkyloxy-,
(3) aryl-C0 -6 alkyloxy-,
(4) C1 -8 alkylcarbonyloxy-C1 -4 alkyloxy-, and
(5) aryl-C 1 -8 alkylcarbonyloxy-C1 -4 alkyloxy-;
D is selected from -SO2- and -C(O)-; and
R6 is selected from:
( 1 ) -C1 -6alkyl, unsusbstituted, mono- or di-substituted with R1 a, (2) -(C0 -6alkyl)aryl, wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(3) -(C0 -6alkyl)heterocycle, wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1 a,
(4) -NR1(C1 -6alkyl), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(5) -NR1(C0 -6alkylaryl), wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1 a,
(6) -NR1(C0 -6alkylheterocycle), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(7) -C3-6 cycloalkyl,
(8) -CF3,
Figure imgf000113_0001
(11 ) when Z is unsubstituted or substituted phenyl, D-R6
together with the nitrogen to which it is attached can form a bicyclic structure with Z (phenyl) as follows:
Figure imgf000113_0002
heterocycle is selected from a five or six membered saturated, partially unsaturated or aromatic ring which is unsubstituted, or
monosubstituted or disubstituted with R1 a, and which consists of carbon atoms and one or two heteroatoms selected from the group -O-, -N-, -N(R1 )- and -S-.
3. The compound of claim 2 wherein X-A- together represent a group selected from:
Figure imgf000114_0002
4. The compound of claim 3 wherein:
Q is selected form -NH-, -O- and -S-;
Y is selected from:
(1 ) -NR1 -CO-,
(2) -CONR1-,
(3) -O-,
(4) -SOp-,
(5) -NR1 -,
(6) -SOp-NR1-,
(7) -CO-, and
(8) -CH(OH)-; p is an integer selected from 0, 1 and 2;
Z is selected from:
(1 ) phenyl,
(2) phenyl which is mono-, di- or tri-substituted with R2,
(3) thienyl,
Figure imgf000114_0001
R1 is independently selected at each occurrence from -H and
-C1-10 alkyl;
R1a is independently selected at each occurrence from -H, halogen and
-C1-10 alkyl;
R2 is independently selected at each occuπence from -H, halogen and
-C1-10 alkyl;
R3 is independently selected at each occurrence from -H and
-C1-10 alkyl;
R5 is selected from:
(1) -OH,
(2) C1-8 alkyloxy-,
(3) aryl-C1-6 alkyloxy-,
(4) C1-8 alkylcarbonyloxy-C1-4 alkyloxy-, and
(5) aryl-C1-8 alkylcarbonyloxy-C1-4 alkyloxy-;
D is selected from -SO2- and -C(O)-; and
R6 is selected from:
(1) -C1-6alkyl, unsusbstituted, mono- or di-substituted with R1a
(2) -(C1-6alkyl)aryl, wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1a,
(3) -(C1-6alkyl)heterocycle, wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1a,
(4) -NR1(C1-6alkyl), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1a,
(5) -NR1(C1-6alkylaryl), wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1a,
(6) -NR1(C1-6alkylheterocycle), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1a,
(7) -C3-6 cycloalkyl,
(8) -CF3,
Figure imgf000116_0001
(1 1 ) when Z is unsubstituted or substituted phenyl, D-R6
together with the nitrogen to which it is attached can form a bicyclic structure with Z (phenyl) as follows:
Figure imgf000116_0002
heterocycle is selected from a five or six membered saturated, partially unsaturated or aromatic ring which is unsubstituted, or
monosubstituted or disubstituted with R1 a, and which consists of carbon atoms and one or two heteroatoms selected from the group -O-, -N-, -N(R1 )-, and -S-.
The compound of claim 4 having the formula III
Figure imgf000116_0003
and the pharmaceutically acceptable salts, solvates and stereoisomers thereof wherein:
Y is selected from:
( 1 ) -NR1 -CO-,
(2) -CONR1 -, (3) -O-,
(4) -SOp-,
(5) -NR1-,
(6) -SOp-NR1-,
(7) -CO-, and
(8) -CH(OH)-; p is an integer selected from 0, 1 and 2;
Z is selected from:
(1 ) phenyl,
(2) phenyl which is mono-, di- or tri-substituted with R2,
(3) thienyl,
Figure imgf000117_0001
R1 is independently selected at each occurrence from -H and
-C1 -10 alkyl;
R1 a is independently selected at each occurrence from -H, halogen and
-C1 - 10 alkyl;
R2 is independently selected at each occurrence from -H, halogen and
-C1 - 10 alkyl;
R3 is independently selected at each occurrence from -H and
-C1 - 10 alkyl;
R5 is selected from:
( 1) -OH,
(2) C1 -8 alkyloxy-,
(3) aryl-C0 -6 alkyloxy-,
(4) C1 -8 alkylcarbonyloxy-C1 -4 alkyloxy-, and
(5) aryl-C1 -8 alky Icarbony loxy-C1 -4 alkyloxy-;
D is selected from -SO2- and -C(O)-; and
R6 is selected from: (1) -C1 -6alkyl, unsusbstituted, mono- or di-substituted with R1 a,
(2) -(C0 -6alkyl)aryl, wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(3) -(C0 -6alkyl)heterocycle, wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1 a,
(4) -NRl(C1 -6alkyl), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(5) -NR1 (C0 -6alkylaryl), wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1 a,
(6) -NR1 (C0 -6alky -heterocycle), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(7) -C3-6 cycloalkyl,
(8) -CF3,
Figure imgf000118_0001
(1 1 ) when Z is unsubstituted or substituted phenyl, D-R6
together with the nitrogen to which it is attached can form a bicyclic structure with Z (phenyl) as follows:
Figure imgf000118_0002
heterocycle is selected from a five or six membered saturated, partially unsaturated or aromatic ring which is unsubstituted, or
monosubstituted or disubstituted with R 1 a, and which consists of carbon atoms and one or two heteroatoms selected from the group -O-, -N-, -N(R1)- and -S-.
6. The compound of claim 5 having the formula IV
Figure imgf000119_0001
and the pharmaceutically acceptable salts, solvates and stereoisomers thereof wherein:
Y is selected from -C(O)-N(R1)- and -N(R1)-C(O)-;
R1 is independently selected at each occurrence from -H and
-C1 -10 alkyl;
R1 a is independently selected at each occurrence from -H, halogen and
-C1 - 10 alkyl;
R2 is independently selected at each occurrence from -H, halogen and -C1 -10 alkyl;
R3 is independently selected at each occurrence from -H and
-C1 - 10 alkyl;
R5 is selected from:
(1 ) -OH,
(2) C1 -8 alkyloxy-,
(3) aryl-C1 -6 alkyloxy-,
(4) C1 -8 alkylcarbonyloxy-C1 -4 alkyloxy-, and
(5) aryl-C1 -8 alkylcarbonyloxy-C1 -4 alkyloxy-;
D is selected from -SO2- and -C(O)-; and
R6 is selected from:
( 1) -C1 -6alkyl, unsusbstituted, mono- or di-substituted with R1 a,
(2) -(C1 -6alkyl)aryl, wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(3) -(C1 -6alkyl)neterocycle, wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1 a, (4) -NR1(C1 -6alkyl), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(5) -NR1(C0 -6alkylaryl), wherein the alkyl group is
unsusbstituted, mono- or di-substituted with R1 a,
(6) -NR1(C0 -6alkylheterocycle), wherein the alkyl group is unsusbstituted, mono- or di-substituted with R1 a,
(7) -C3-6 cycloalkyl,
(8) -CF3,
Figure imgf000120_0001
(1 1 ) when Z is unsubstituted or substituted phenyl, D-R6
together with the nitrogen to which it is attached can form a bicyclic structure with Z (phenyl) as follows:
Figure imgf000120_0002
heterocycle is selected from a five or six membered saturated, partially unsaturated or aromatic ring which is unsubstituted, or
monosubstituted or disubstituted with R1 a, and which consists of carbon atoms and one or two heteroatoms selected from the group -O-, -N-, -N(R1 )- and -S-.
7. The compound of claim 6 wherein Y is selected from -C(O)-NH- and -NH-C(O)-; and R6 is selected from (1) unsubstitutee, mono and di-substituted phenyl, (2) methyl, (3) benzyl wherein the aryl portion may be unsubstituted, mono or di-substituted, and (4) thienyl.
8. The compound of claim 1 wherein Y is -C(O)-NH-.
9. The compound of claim 8 having the formula V wherein R1 a, R2, R5, D, and R6 are defined as follows:
Figure imgf000121_0001
Figure imgf000121_0002
Figure imgf000122_0001
10. The compound of claim 9 selected from those wherein:
a) R1 a is H, R2 is H, R5 is OH, D is -SO2-, and R6 is phenyl; and b) R 1 a is H, R2 is H, R5 is OH, D is -SO2-, and R6 is 2-thiophene.
1 1. The compound of claim 1 wherein Y is -NH-C(O)-
12. The compound of claim 1 1 having the formula VI wherein Z, R5 and R6 are defined as follows:
Figure imgf000123_0001
)
Figure imgf000123_0003
13. The compound of claim 12 selected from those wherein Z R5 and R6 are defined as follows:
Figure imgf000123_0004
14. The compound of claim 1 having the formula VII wherein X-A, Y, Z and n are defined as follows:
Figure imgf000123_0002
Figure imgf000124_0001
15. The use of a compound of Claim 1 for inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, or preventing thrombus or embolus formation in a mammal.
16. A composition for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.
17. A composition for inhibiting the aggregation of blood platelets in a mammal, by blocking fibrinogen from acting at its receptor site, comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.
18. A composition for inhibiting the aggregation of blood platelets in a mammal, by blocking fibrinogen from acting at its receptor site, comprising a therapeutically effective amount of a compound of Claim 1 in combination with a thrombolytic agent and a pharmaceutically acceptable carrier.
19. A composition for inhibiting the aggregation of blood platelets in a mammal, by blocking fibrinogen from acting at its receptor site, comprising a therapeutically effective amount of a compound of Claim 1 in combination with an anticoagulant agent and pharmaceutically acceptable carrier.
20. A method for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising treating the mammal with a composition of Claim 16.
21. A method for inhibiting the aggregation of blood platelets in a mammal, by blocking fibrinogen from acting at its receptor site, comprising treating the mammal with a composition of Claim 17.
22. A method for inhibiting the aggregation of blood platelets in a mammal, by blocking fibrinogen from acting at its receptor site, comprising treating the mammal with a composition of Claim 18.
23. A method for inhibiting the aggregation of blood platelets in a mammal, by blocking fibrinogen from acting at its receptor site, comprising treating the mammal with a composition of Claim 19.
24. A composition for inhibiting the aggregation of blood platelets in a mammal, by blocking fibrinogen from acting at its receptor site, comprising a a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1 in
combination with a therapeutically effective amount of two or more agents selected from a thrombolytic agent, an anticoagulant agent, and an antiplatelet agent.
25. A method for inhibiting the aggregation of blood platelets in a mammal, by blocking fibrinogen from acting at its receptor site, comprising treating the mammal with the composition of Claim 24.
26. A compound of Claim 6 for use in inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, or preventing thrombus or embolus formation in a mammal.
27. A composition for inhibiting the binding of fibrinogen to blood platelets, in a mammal, comprising a therapeutically effective amount of a compound of Claim 6 and a pharmaceutically acceptable carrier.
28. A composition for inhibiting the aggregation of blood platelets, in a mammal, by blocking fibrinogen from acting at its receptor site, comprising a therapeutically effective amount of a compound of Claim 6 and a pharmaceutically acceptable carrier.
29. A method for inhibiting the binding of fibrinogen to blood platelets in a mammal, by blocking fibrinogen from acting at its receptor site, comprising treating the mammal with a composition of Claim 27.
30. A method for inhibiting the aggregation of blood platelets in a mammal, by blocking fibrinogen from acting at its receptor site, comprising treating the mammal with a composition of Claim 28.
PCT/US1997/002712 1996-02-28 1997-02-24 Fibrinogen receptor antagonists WO1997031910A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU21332/97A AU712082B2 (en) 1996-02-28 1997-02-24 Fibrinogen receptor antagonists
EP97906712A EP0885205A4 (en) 1996-02-28 1997-02-24 Fibrinogen receptor antagonists
JP9531013A JP2000505471A (en) 1996-02-28 1997-02-24 Fibrinogen receptor antagonist

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1238096P 1996-02-28 1996-02-28
US60/012,380 1996-02-28
GBGB9606489.4A GB9606489D0 (en) 1996-03-27 1996-03-27 Fibrinogen receptor antagonists
GB9606489.4 1996-03-27

Publications (1)

Publication Number Publication Date
WO1997031910A1 true WO1997031910A1 (en) 1997-09-04

Family

ID=26309005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/002712 WO1997031910A1 (en) 1996-02-28 1997-02-24 Fibrinogen receptor antagonists

Country Status (5)

Country Link
EP (1) EP0885205A4 (en)
JP (1) JP2000505471A (en)
AU (1) AU712082B2 (en)
CA (1) CA2246756A1 (en)
WO (1) WO1997031910A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0912175A1 (en) * 1996-06-28 1999-05-06 Merck & Co., Inc. Fibrinogen receptor antagonists
JP2001026506A (en) * 1999-04-28 2001-01-30 Takeda Chem Ind Ltd Sulfonamide derivative
WO2001016119A1 (en) * 1999-08-27 2001-03-08 Eli Lilly And Company Hypoglycemic n,n-arylsulfonylglycine compounds
EP1174028A1 (en) * 1999-04-28 2002-01-23 Takeda Chemical Industries, Ltd. Sulfonamide derivatives
WO2002102780A1 (en) * 2001-06-18 2002-12-27 Ono Pharmaceutical Co., Ltd. Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
US6642252B2 (en) 2000-11-07 2003-11-04 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
US6713467B2 (en) 2000-11-07 2004-03-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
WO2005049589A2 (en) * 2003-10-14 2005-06-02 Cadila Healthcare Limited Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
US6906192B2 (en) 2000-11-07 2005-06-14 Bristol Myers Squibb Company Processes for the preparation of acid derivatives useful as serine protease inhibitors
US7786155B2 (en) 2007-10-16 2010-08-31 Novartis Ag Organic compounds
US8012982B2 (en) 2004-10-01 2011-09-06 Istituto Di Ricerche Biologia Molecolare P. Angeletti Spa Modulators of HCV replication
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8637501B2 (en) 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US10562912B2 (en) 2013-06-05 2020-02-18 C&C Research Laboratories Heterocyclic derivatives and use thereof
US10710986B2 (en) 2018-02-13 2020-07-14 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10752640B2 (en) 2014-08-01 2020-08-25 Nuevolution A/S Compounds active towards bromodomains
US10774071B2 (en) 2018-07-13 2020-09-15 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1910290A2 (en) * 2005-06-30 2008-04-16 Prosidion Limited Gpcr agonists
WO2011027888A1 (en) * 2009-09-07 2011-03-10 大日本住友製薬株式会社 Diamide-phenyl derivative and pharmaceutically acceptable salt thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760064A (en) * 1984-12-18 1988-07-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
US5183810A (en) * 1990-02-13 1993-02-02 Merck & Co., Inc. Imidazole angiotensin II antagonists incorporating a substituted benzyl element
US5464833A (en) * 1992-08-19 1995-11-07 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulating composition
US5556977A (en) * 1993-03-29 1996-09-17 Zeneca Limited Heterocyclic derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56115769A (en) * 1980-02-18 1981-09-11 Tanabe Seiyaku Co Ltd Piperazine derivative and its preparation
DE3622865A1 (en) * 1986-07-08 1988-01-21 Bayer Ag N-Phenyl-substituted glycines
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
JPH04182481A (en) * 1990-11-19 1992-06-30 Nisshin Flour Milling Co Ltd Rhodanine derivative
US5358956A (en) * 1992-10-14 1994-10-25 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH08504194A (en) * 1992-12-01 1996-05-07 メルク エンド カンパニー インコーポレーテッド Fibrinogen receptor antagonist
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US5700801A (en) * 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760064A (en) * 1984-12-18 1988-07-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
US5183810A (en) * 1990-02-13 1993-02-02 Merck & Co., Inc. Imidazole angiotensin II antagonists incorporating a substituted benzyl element
US5464833A (en) * 1992-08-19 1995-11-07 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulating composition
US5556977A (en) * 1993-03-29 1996-09-17 Zeneca Limited Heterocyclic derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0885205A4 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0912175A4 (en) * 1996-06-28 1999-09-08 Merck & Co Inc Fibrinogen receptor antagonists
EP0912175A1 (en) * 1996-06-28 1999-05-06 Merck & Co., Inc. Fibrinogen receptor antagonists
US6586617B1 (en) 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
JP2001026506A (en) * 1999-04-28 2001-01-30 Takeda Chem Ind Ltd Sulfonamide derivative
EP1174028A1 (en) * 1999-04-28 2002-01-23 Takeda Chemical Industries, Ltd. Sulfonamide derivatives
EP1174028A4 (en) * 1999-04-28 2002-11-06 Takeda Chemical Industries Ltd Sulfonamide derivatives
US6617343B1 (en) 1999-08-27 2003-09-09 Eli Lilly And Company Hypoglycemic N,N-arylsulfonylglycine compounds
WO2001016119A1 (en) * 1999-08-27 2001-03-08 Eli Lilly And Company Hypoglycemic n,n-arylsulfonylglycine compounds
US6642252B2 (en) 2000-11-07 2003-11-04 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
US6713467B2 (en) 2000-11-07 2004-03-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
US6906192B2 (en) 2000-11-07 2005-06-14 Bristol Myers Squibb Company Processes for the preparation of acid derivatives useful as serine protease inhibitors
WO2002102780A1 (en) * 2001-06-18 2002-12-27 Ono Pharmaceutical Co., Ltd. Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
WO2005049589A2 (en) * 2003-10-14 2005-06-02 Cadila Healthcare Limited Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
WO2005049589A3 (en) * 2003-10-14 2005-09-15 Cadila Healthcare Ltd Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
US8012982B2 (en) 2004-10-01 2011-09-06 Istituto Di Ricerche Biologia Molecolare P. Angeletti Spa Modulators of HCV replication
US7786155B2 (en) 2007-10-16 2010-08-31 Novartis Ag Organic compounds
US9650378B2 (en) 2008-01-11 2017-05-16 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US9296743B2 (en) 2008-01-11 2016-03-29 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US8637501B2 (en) 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US10562912B2 (en) 2013-06-05 2020-02-18 C&C Research Laboratories Heterocyclic derivatives and use thereof
US10752640B2 (en) 2014-08-01 2020-08-25 Nuevolution A/S Compounds active towards bromodomains
US10710986B2 (en) 2018-02-13 2020-07-14 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11555029B2 (en) 2018-02-13 2023-01-17 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10774071B2 (en) 2018-07-13 2020-09-15 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors

Also Published As

Publication number Publication date
JP2000505471A (en) 2000-05-09
CA2246756A1 (en) 1997-09-04
EP0885205A4 (en) 2002-11-27
EP0885205A1 (en) 1998-12-23
AU2133297A (en) 1997-09-16
AU712082B2 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
AU712082B2 (en) Fibrinogen receptor antagonists
US5719162A (en) Fibrinogen receptor antagonists
US5786373A (en) Fibrinogen receptor antagonists
US5227490A (en) Fibrinogen receptor antagonists
JP2552986B2 (en) Fibrinogen receptor antagonist
US6515011B2 (en) Thrombin inhibitors
WO1997014417A1 (en) Fibrinogen receptor antagonists
US5334596A (en) Fibrinogen receptor antagonists
US5780480A (en) Fibrinogen receptor antagonists
US5397791A (en) Fibrinogen receptor antagonists
US5932582A (en) Fibrinogen receptor antagonist prodrugs
US5358956A (en) Fibrinogen receptor antagonists
US5821241A (en) Fibrinogen receptor antagonists
US5451578A (en) Fibrinogen receptor antagonists
US5852045A (en) Fibrinogen receptor antagonists
US5494921A (en) Fibrinogen receptor antagonists
US5525617A (en) Fibrinogen receptor antagonists
US5952306A (en) Integrin receptor antagonists
US5789421A (en) Fibrinogen receptor antagonist
US5889023A (en) Fibrinogen receptor antagonist
AU702025B2 (en) Fibrinogen receptor antagonist
GB2312895A (en) Fibrinogen receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2246756

Country of ref document: CA

Ref country code: CA

Ref document number: 2246756

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997906712

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997906712

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997906712

Country of ref document: EP